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Abstract 
 
Glaucoma is a multifactorial condition caused, in part, by fibrosis of the sieve-like 
trabecular meshwork (TM) tissue, which impedes drainage of aqueous humor (AH), 
leading to increased intraocular pressure and associated optic nerve damage and 
blindness.  Fibrosis of the TM is mainly caused by the increased levels of active 
transforming growth factor-β 2 (TGFβ2) in the AH of glaucoma patients.   
 
Previous reports have shown that TGFβ decreases the expression of Phosphatase 
and Tensin Homolog (PTEN) gene and that PTEN is a major regulator of ECM 
deposition.  In this study we investigate the regulation of PTEN protein expression and 
activity by TGFβ2 in TM cells to determine the mechanism by which excess ECM is 
deposited.  
 
Here we show that TGFβ2 induces collagen deposition in TM cells by phosphorylation 
of PTEN, a mechanism that is known to inactivate PTEN. Phosphorylation of PTEN 
by TGFβ is novel and has not been previously reported.  We have found that PTEN 
protein expression and phosphorylation is regulated by the PI3 kinase pathway.  We 
further show that transfection of TM cells to express enhanced-active PTEN 
decreases TGFβ2-induced expression of collagen type I (COL1) protein.  Thus, 
regulation of PTEN activity could serve as a therapeutic target with high potential to 
prevent excess ECM deposition in the TM of glaucoma patients. 
 
Keywords: 
Glaucoma, trabecular meshwork (TM), Phosphatase and Tensin Homolog (PTEN), 
excess extracellular matrix (ECM) deposition, fibrosis, aqueous outflow resistance, 
transforming growth factor-β (TGFβ2) 
 ii 
 
 Acknowledgments  
 
My deepest gratitude goes to my supervisor Dr. Sunil K. Parapuram, for providing me 
with the opportunity to work on this wonderful project.  Thank you for your continued 
insight, guidance, and patience as I embarked on the road to becoming a better 
researcher and intellectual.  
 
I would like to acknowledge my advisory committee, Dr. Martin Duennwald, Dr. 
Andrew Leask, and Dr. David O’Gorman, for their knowledge, encouragement, and 
humor.  I always left our committee meetings with renewed fervor for my work and 
new complexities to ponder. 
 
Thank you to Hong Liu, for her kind help and support within the Ophthalmology 
research lab. 
 
I would also like to acknowledge Dr. M. Iijima for generously providing mutated-PTEN 
vectors from her lab.  The experiments conducted with these vectors were integral to 
illustrating a portion of our PTEN narrative. 
 
Finally, I would like to thank my family for their continued support and avid 
encouragement of my academic endeavors.     
 iii 
 
Table of Contents 
Abstract ................................................................................................................. i 
Acknowledgments .................................................................................................ii 
Table of Contents ................................................................................................. iii 
List of Tables ....................................................................................................... vii 
List of Figures ..................................................................................................... viii 
List of Abbreviations ............................................................................................. x 
List of Appendices ...............................................................................................xv 
Overview ............................................................................................................ xvi 
Chapter 1 .............................................................................................................. 1 
1 Introduction ...................................................................................................... 1 
1.1 Aqueous Humor and Outflow ..................................................................... 1 
1.2 The Trabecular Meshwork Tissue .............................................................. 3 
1.2.1 Trabecular Meshwork Tissue Structure ........................................... 3 
1.2.2 Trabecular Meshwork Tissue Function ........................................... 4 
1.3 Glaucoma .................................................................................................. 6 
1.3.1 Epidemiology and Classification...................................................... 6 
1.3.2 Pathogenesis .................................................................................. 6 
1.3.3 Risk Factors .................................................................................... 7 
1.3.4 Diagnosis and Treatment Options ................................................... 8 
1.4 Fibrosis ...................................................................................................... 9 
1.5 Transforming Growth Factor β ................................................................. 10 
1.5.1 Ocular TGFβ ................................................................................. 11 
1.5.2 TGFβ Signaling ............................................................................. 12 
1.6 Phosphatase and Tensin Homolog .......................................................... 14 
 iv 
 
1.6.1 PTEN Structure and Function ....................................................... 14 
1.7 Hypothesis and Objectives ...................................................................... 16 
1.7.1 Hypothesis .................................................................................... 16 
1.7.2 Objectives ..................................................................................... 16 
Chapter 2 ............................................................................................................ 17 
2 Materials and Methods ................................................................................... 17 
2.1 Human Donor Trabecular Meshwork Cell Culture ................................... 17 
2.2 Cellular Transfection ................................................................................ 18 
2.2.1 Subcloning and Purification of Bacterial Plasmids ........................ 19 
2.3 RNA Isolation and RT-PCR ..................................................................... 19 
2.4 Protein Isolation and Immunoblotting ....................................................... 20 
2.5 Statistical Analysis ................................................................................... 22 
Chapter 3 ............................................................................................................ 23 
3 Modulation of PTEN by TGFβ2 ...................................................................... 23 
3.1 Rationale .................................................................................................. 23 
3.2 Background .............................................................................................. 23 
3.3 Experimental Approach............................................................................ 27 
3.4 Results ..................................................................................................... 28 
3.4.1 TGFβ2 increases COL1A1 mRNA expression. ............................. 28 
3.4.2 TGFβ2 increases PTEN mRNA expression. ................................. 29 
3.4.3 COL1 protein expression after TGFβ2 treatment. ......................... 30 
3.4.4 TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN. ........................................................................................... 31 
3.4.5 Summary of Results ...................................................................... 35 
3.5 Discussion ............................................................................................... 35 
Chapter 4 ............................................................................................................ 38 
 v 
 
4 Signaling mechanisms regulating PTEN ........................................................ 38 
4.1 Rationale .................................................................................................. 38 
4.2 Background .............................................................................................. 39 
4.2.1 PI3K/AKT Pathway ........................................................................ 39 
4.2.2 Src/FAK Pathway .......................................................................... 41 
4.3 Experimental Approach............................................................................ 43 
4.4 Results ..................................................................................................... 44 
4.4.1 PI3K/AKT Pathway ........................................................................ 44 
4.4.2 Src/FAK ......................................................................................... 58 
4.4.3 Summary of Results ...................................................................... 67 
4.5 Discussion ............................................................................................... 67 
Chapter 5 ............................................................................................................ 72 
5 The functional role of PTEN in the ECM of the TM ........................................ 72 
5.1 Rationale .................................................................................................. 72 
5.2 Background .............................................................................................. 72 
5.3 Experimental Approach............................................................................ 74 
5.4 Results ..................................................................................................... 75 
5.4.1 Expression of COL1 protein after inhibition of PTEN. ................... 75 
5.4.2 Expression of enhanced-active PTEN prevents increased COL1 
protein expression. ........................................................................ 77 
5.4.3 Expression of enhanced-active PTEN decreases phosphorylation of 
PTEN. ........................................................................................... 79 
5.4.4 Summary of Results ...................................................................... 81 
5.5 Discussion ............................................................................................... 81 
Chapter 6 ............................................................................................................ 84 
6 Conclusions .................................................................................................... 84 
6.1 Summary of Results................................................................................. 84 
 vi 
 
6.2 Limitations of the Study............................................................................ 87 
6.3 Future Directions ..................................................................................... 88 
6.4 Concluding Remarks................................................................................ 90 
7 References ..................................................................................................... 91 
Appendices ....................................................................................................... 107 
Curriculum Vitae ............................................................................................... 110 
 vii 
 
List of Tables  
Table 2.1.1. List of Treatments Used for Cell Culture. ..............................................17 
Table 2.4.1. List of Antibodies Used for Immunoblotting. .........................................21 
 
 viii 
 
List of Figures  
Figure 1.1.1 Schematic and electron-micrograph images of the TM. ........................ 2 
Figure 1.2.1 Schematic representation of increased ECM in glaucomatous TM 
tissue. ........................................................................................................................ 5 
Figure 1.5.1 Canonical TGFβ signaling. ...................................................................13 
Figure 3.2.1. Open and Closed PTEN conformation. ...............................................27 
Figure 3.4.1 TGFβ2 increases COL1A1 mRNA expression. ....................................28 
Figure 3.4.2 TGFβ2 increases PTEN mRNA expression. .........................................29 
Figure 3.4.3 COL1 protein expression after TGFβ2 treatment. ................................30 
Figure 3.4.4 TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN at 24 hours. ....................................................................................................32 
Figure 3.4.5 TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN at 48 hours. ....................................................................................................34 
Figure 4.2.1 Schematic representation of PI3K/AKT pathway with active and inactive 
PTEN. .......................................................................................................................40 
Figure 4.4.1 TGFβ2 increases phosphorylation of AKT at 24 hours. ........................45 
Figure 4.4.2 Expression of phosphorylated AKT 48 hours after TGFβ2 treatment. ..46 
Figure 4.4.3 Inhibition of PI3K with LY294002 decreases COL1 protein expression.
 .................................................................................................................................48 
Figure 4.4.4 Inhibition of PI3K with LY294002 decreases PTEN protein expression 
and phosphorylation. ................................................................................................50 
Figure 4.4.5 Phosphorylation of AKT after inhibition of PI3K with LY294002. ..........51 
 ix 
 
Figure 4.4.6 Inhibition of PI3K with ZSTK474 decreases COL1 protein expression. 53 
Figure 4.4.7 Inhibition of PI3K with ZSTK474 decreases PTEN protein expression 
and phosphorylation. ................................................................................................55 
Figure 4.4.8 Inhibition of PI3K with ZSTK474 decreases phosphorylation of AKT. ..57 
Figure 4.4.9 Phosphorylation of FAK 24 hours after TGFβ2 treatment. ...................59 
Figure 4.4.10 Phosphorylation of FAK 48 hours after TGFβ2 treatment...................60 
Figure 4.4.11 Inhibition of Src/FAK decreases COL1 protein expression. ................62 
Figure 4.4.12 Inhibition of Src/FAK decreases PTEN protein expression and 
phosphorylation. .......................................................................................................64 
Figure 4.4.13 Inhibition of Src/FAK shows no consistent change in phosphorylation 
of FAK at 24 hours. ...................................................................................................66 
Figure 4.5.1. Schematic representation of proposed TGFβ activation of Src/FAK and 
PI3K recruitment. ......................................................................................................70 
Figure 5.4.1 Expression of COL1 protein after inhibition of PTEN. ...........................76 
Figure 5.4.2 Expression of enhanced-active PTEN prevents increased COL1 protein 
expression. ...............................................................................................................78 
Figure 5.4.3 Expression of enhanced-active PTEN decreases TGFβ2-induced 
phosphorylation of PTEN. .........................................................................................80 
Figure 6.1.1. Summary of Experimental Study. ........................................................85 
Figure 6.1.2 Summary Diagram of Fibrotic Pathways Involved in TGFβ signaling. ..86 
  
 x 
 
List of Abbreviations 
AH          Aqueous humor 
AKT          Protein kinase B 
ALK5          Activin A receptor type II-like kinase (TGFβR I) 
Amp          Ampicillin 
ANOVA         Analysis of variance 
BSA          Bovine serum albumin 
C124S PTEN        PTEN with cysteine to serine substitution at position 124 
C124SV         C124S PTEN vector 
C2 domain Conserved domain of Protein kinase C targeting protein to the        
plasma membrane 
COL1A1         Collagen I gene 
COL1                  Collagen I protein 
CTM         Corneoscleral trabecular meshwork 
CV          Control vector 
DMEM         Dulbecco’s Modified Eagle Medium 
E. coli          Escherichia coli 
ECL          Enhanced chemiluminescence 
ECM          Extra cellular matrix 
EDTA          Ethylene-diamine-tetra-acetic acid 
ePTEN         Enhanced-active PTEN 
 xi 
 
Euk 18S         Eukaryotic 18S rRNA  
eV          Enhanced-active PTEN vector 
FAK          Focal adhesion kinase 
FBS          Fetal bovine serum 
GAPDH         Glyceraldehyde 3-phosphate dehydrogenase 
GSK          Glycogen synthase kinase 
HRP          Horseradish peroxidase 
hTM          Human trabecular meshwork 
IgG          Immunoglobulin G 
IOP          Intraocular pressure 
IP          Immunoprecipitation 
JCT          Juxtacanalicular trabecular meshwork 
LAP          Latency associated peptide 
LB          Lennox broth 
LY20          LY294002 20µM 
LY30                    LY294002 30µM 
mAb          Monoclonal antibody  
MAP          Mitogen activated protein  
MKK3/6         Map kinase kinase 3 and 6 
MMAC1         Mutated in multiple advanced cancers 1 
 xii 
 
MMP          Matrix metalloproteinase 
mRNA         Messenger RNA 
NF-κB          Nuclear factor kappa light-chain-enhancer of activated B cells 
ng/mL          Nanograms per milliliter 
pAb          Polyclonal antibody 
P10          PP2 10µM 
P20                    PP2 20µM 
pAKT          AKT phosphorylated at Ser473 
pFAK          FAK phosphorylated at Tyr397 
PBS          Phosphate-buffered saline 
PI          Phosphatase Inhibitor  
PI3K          Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIP2          Phosphatidylinositol 4,5-bisphosphate 
PIP3          Phosphatidylinositol 3,4,5-trisphosphate 
pg/mL                  Picograms per milliliter 
POAG          Primary open angle glaucoma 
pPTEN         PTEN phosphorylated at Ser380/Thr382/383 
P/S          Penicillin/Streptomycin 
pSMAD         Phosphorylated SMAD 
PTEN          Phosphatase and Tensin Homolog gene 
 xiii 
 
PTEN          Phosphatase and Tensin Homolog protein 
RAK          Fly-related kinase (FRK) 
RGCs          Retinal ganglion cells 
RNA          Ribonucleic acid 
rRNA          Ribosomal ribonucleic acid 
RTK          Receptor tyrosine kinase 
ROCK          Rho-associated protein kinase 
RT-PCR         Real time – Polymerase chain reaction 
SARA          SMAD anchor for receptor activation 
SB20          SB431542 20µM 
SC          Schlemm’s Canal 
SDS-PAGE         Sodium dodecyl sulfate – Polyacrylamide gel electrophoresis 
Ser          Serine 
Shc           Src homology 2 domain containing transforming protein 
si-RNA         Small interfering RNA 
SLT          Selective laser trabeculoplasty 
SMAD Homolg of SMA (small body size) and MAD (mothers against 
decapentaplegic) protein 
SPARC         Secreted protein acidic and rich in cysteine 
Src          Tyrosine protein kinase Src 
T1          TGFβ2 1ng/mL 
 xiv 
 
T5          TGFβ2 5ng/mL 
T10          TGFβ2 10ng/mL 
TAK1          Transforming growth factor β activated kinase 
TEP1          TGFβ regulated and epithelial cell enriched phosphatase 1 
TGFβ2         Transforming growth factor β 2 
TGFβR I         Transforming growth factor β receptor I 
TGFβR II         Transforming growth factor β receptor II 
Thr         Threonine 
Tyr          Tyrosine 
TIMPs          Tissue inhibitors of metalloproteinases 
TM          Trabecular meshwork 
TRAF6         TNF receptor associated factor 6 
Z2          ZSTK474 2µM 
Z5                    ZSTK474 5µM  
 
 
 
 
 
 
 xv 
 
List of Appendices  
Appendix A: TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN on plastic plates. ..........................................................................................107 
Appendix B: TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN on COL1-coated plates. ...............................................................................107 
Appendix C: TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN at early time points. ......................................................................................108 
Appendix D: TGFβ2 increases AKT phosphorylation at early time points. ............109 
 
 
 
 xvi 
 
Overview 
Glaucoma is a complex and heterogeneous disease characterized by progressive 
degeneration of the optic nerve and vision loss.  Glaucoma affects more than 70 
million people worldwide and is currently the second leading cause of irreversible 
blindness (1).  In Canada, primary open-angle glaucoma (POAG), the most common 
form of glaucoma, is expected to increase by 105% by 2031 (2).  
It has been shown that fibrosis of the trabecular meshwork (TM) tissue in POAG 
patients (3, 4) is associated with increased levels of active of TGFβ2 present in the 
AH (5).  Since the TM is responsible for filtering and draining aqueous humor (AH), 
fibrosis of the TM tissue have downstream physiological effects.  Primarily, increased 
thickness of the TM decreases the size of pores within the tissue, which results in 
increased resistance to AH outflow (3, 4).   
As the dynamics of AH outflow shift and drainage of AH decreases, intraocular 
pressure (IOP) increases.  Elevated IOP is a hallmark of glaucoma and remains, to 
date, the only modifiable risk factor of the disease.  As such, chronically elevated IOP 
can cause irreparable damage to the optic nerve and permanent vision loss (6).  
Therapies aimed at preventing increases in IOP should thus target fibrosis of the TM, 
however, this is yet to be achieved. 
TGFβ is known to modulate the expression of protein Phosphatase and Tensin 
Homolog (PTEN) deleted on chromosome 10, which is a major regulator of ECM 
deposition (7, 8,).  However, no study has examined the role of PTEN in regulating 
the ECM turnover in the TM. 
We hypothesize that TGFβ2 regulates ECM deposition in the TM by modulating the 
expression and activity of PTEN, and that a decrease in PTEN expression or activity 
causes fibrosis of the TM in glaucoma patients. 
To test this hypothesis we proposed the following approach of investigation: 
 
1. To determine how TGFβ2 modulates PTEN expression and activity. 
 xvii 
 
2. To identify mechanisms by which PTEN is regulated by downstream TGFβ 
signaling pathways. 
3. To characterize the functional role of PTEN in the ECM of the TM. 
Our data show that TGFβ2 regulates collagen I expression in hTM cells by 
phosphorylating PTEN. We found that TGFβ2-induced phosphorylation of PTEN, 
which is known to inactivate PTEN, is mediated by the PI3 kinase/AKT signaling 
pathway.  Furthermore, we show that overexpression of PTEN with an eight-fold 
increase in enzymatic activity, compared to wild-type PTEN, prevented TGFβ2-
induced collagen expression in TM cells. 
These results support our hypothesis and provide insight into a novel mechanism by 
which PTEN regulates fibrosis of the TM.  Since little is known about the development 
and progression of glaucoma, our findings have great potential to establish part of the 
pathogenesis of this disease and guide development of targeted therapies.  Further 
investigation is crucial as PTEN has high clinical potential as a target to address 
excess ECM deposition in the TM, and ultimately mitigate the risk of vision loss for 
glaucoma patients. 
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Chapter 1  
1 Introduction 
1.1 Aqueous Humor and Outflow 
AH is a clear fluid normally found within the anterior segment of the eye.  It is 
comprised mostly of water and contains an extremely low protein concentration, 
which maintains optical clarity.  Ions essential to cell function, including hydrogen, 
chloride, and bicarbonate, are present along with cytokines, growth factors, and 
low levels of circulating enzymes (9).   
Production of AH occurs posteriorly by the inner epithelial cells of the ciliary body. 
AH is then actively secreted by the ciliary processes and flows around the iris into 
the anterior segment (4, 9).  Of the many functions of AH, most notably it is required 
to: 
1. Maintain IOP and sustain the spherical shape of the eye by filling the space 
between the cornea and the lens to avoid collapse. 
2. Provide nourishment to the avascular structures of the anterior segment, 
particularly the lens and the cornea. 
3. Serve as a means to rid cells in avascular structures of accumulated waste 
products. 
Roughly 85% of total AH outflow occurs through the trabecular meshwork, or 
conventional outflow pathway.  Traveling along the conventional pathway, AH 
drains through the progressively smaller pores of the TM to gain entry into 
Schlemm’s canal (as illustrated in Figure 1.2.1).  Once in Schlemm’s canal, AH 
will exit the eye via the episcleral venous system (4, 9).  
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Figure 1.1.1 Schematic and electron-micrograph images of the TM. 
 (A) Schematic representation of the layers and meshwork structure of the TM.  TM tissue lines the 
entrance to Schlemm’s Canal (SC) (red arrow).  Pore size decreases with increased proximity to 
Schlemm’s Canal.  Adapted from: Hogan, Michael J. (Michael John) & Alvarado, Jorge A & 
Weddell, Joan Esperson (1971). Histology of the human eye: an atlas and textbook. Saunders, 
Philadelphia. (10). (B) Electron-micrograph image of a cross-section of the TM.  Large pores 
between beams are visible in the CTM region.  In the JCT region beams are less obvious and pores 
are smaller.  Adapted from: Tamm, E. R. (2009). The trabecular meshwork outflow pathways: 
structural and functional aspects. Experimental eye research, 88(4), 648-655. (9).  
The remaining 15% of AH outflow occurs via the non-conventional uveal scleral 
outflow.  Outflow through the non-conventional pathway occurs as AH diffuses 
through intercellular spaces among ciliary muscles fibers in the posterior chamber 
to enter suprachoroidal spaces (11, 12).  Eventually AH exits the eye through 
vessels in the sclera. 
Under physiological conditions, a homeostatic balance between production and 
drainage of AH must be maintained.  Since AH is continuously produced, at a rate 
between 2.0-2.75µL/min (9, 13), efficient drainage at an equal rate is required to 
avoid changes in IOP. 
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1.2 The Trabecular Meshwork Tissue 
1.2.1 Trabecular Meshwork Tissue Structure 
The trabecular meshwork (TM) tissue is a structured network of cells and 
interconnected beams of extracellular matrix (ECM) that lines the entrance to 
Schelmm’s Canal present at the angle where the cornea meets the iris (Figure 
1.1.1.A).  Cells of the TM tissue have an endothelial morphology (14) and exhibit 
contractile properties as well as phagocytic ability (4).  The core of each beam is 
collagen and elastic-like fibers, surrounded by the TM cells themselves (3, 4).  
Together, the TM cells and beams form a multi-layered, porous structure, which 
serves as the major outflow pathway for the AH of the eye (14).   
Anatomically, the TM is divided into three sections beginning with the corneoscleral 
TM, located most medially.  The uveal TM is located immediately distal of the 
corneoscleral TM.  Finally, the juxtacanalicular (JCT) TM is adjacent to Schlemm’s 
canal.  While there are no physiological markers to distinguish one section of the 
TM from another, the classification is based on anatomical position and 
morphology (4, 9, 10).  The size of the pores between adjacent beams in the TM 
become smaller moving outward from the corneoscleral trabecular meshwork 
(CTM) to the uveal TM.  In the JCT region, individual beams are less obvious as 
the surrounding ECM is compounded in a more irregular fashion, creating a denser 
layer with small pores (Figure 1.1.1). The successive decrease in pore size serves 
to filter AH as it drains from the anterior segment of the eye (4, 9, 10). 
 
ECM is a major component of the TM tissue. The ECM of the TM tissue consists 
of collagens, proteoglycans, adhesive glycoproteins, and elastin (14).  While 
fibrillary collagens type I and III are the most abundant, collagens type IV, V, VI, 
and VII are also expressed in the TM (14), as confirmed by immunostaining (15).  
In cultured TM cells, collagen I is the major type of collagen expressed (14).  
Proteoglycans expressed include chondroitin, dermatan, decorin, and versican, as 
determined by immunohistochemical analysis and RT-PCR (14, 16-18).  Decorin 
is important for maintaining ECM structure as it binds collagen type I promoting 
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collagen fibrillogenesis and proper collagen fibril assembly (14, 19).  Of the 
adhesive glycoproteins expressed in the TM, fibronectin and laminin are the most 
abundant.  Fibronectin is insoluble and localized to the beams of the TM (17, 20).  
Laminin is associated with the basement membrane (17).  Both are important for 
cellular adherence to the ECM. 
 
Finally, elastin is also abundantly expressed in the ECM of the TM.  High 
expression of elastin is consistent with a tissue type that must be able to reversibly 
distend in response to fluctuations of an outside force (14).  Correlating tissue 
structure to function, we find a role for the TM in adapting to changes in IOP. 
1.2.2 Trabecular Meshwork Tissue Function 
Under normal physiological conditions, TM cells can detect changes in IOP and 
induce ECM turnover to maintain adequate outflow of AH and control IOP.  
Specifically, TM cells in the JCT region are able to sense changes in IOP through 
integrins, and alter signaling to remodel ECM accordingly (21).  When the TM 
tissue becomes dysfunctional, signals to remodel the ECM are disrupted such that 
accommodations are not made to increase AH outflow, and IOP remains elevated.  
The perpetuating nature of this paradigm, with increased TM dysfunction (possibly 
due to increased cross-linking of the ECM (22)), causing decreased sensitivity to 
IOP changes creates a  positive feedback loop to further increase IOP and the risk 
of damage caused by sustained elevated pressure (23, 24).  
In regards to contractility and TM function, relaxation of the TM tissue increases 
space between the individual beams, widening pores to increase aqueous outflow.  
Contraction of the TM tissue decreases outflow by bringing pores closer together 
to decrease pore diameter.  Outflow through the TM is pressure-dependent, 
moving along a gradient of high pressure in the anterior chamber to low pressure 
in the episcleral venous system, ensuring unidirectional flow of AH (4). In POAG 
thicker beams of TM tissue have been observed (Figure 1.2.2), such that excess 
ECM deposition narrows pores in the meshwork to increase resistance to aqueous 
outflow (3, 4, 24, 25).  Downstream effects of increased outflow resistance are 
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increased IOP, and resultant degeneration of the optic nerve and eventual 
blindness.  
 
Figure 1.2.1 Schematic representation of increased ECM in glaucomatous 
TM tissue. 
ECM surrounds core beams in the TM tissue.  The TM tissue of normal eyes (left) has sufficient 
space between beams to facilitate drainage of AH.  Increased ECM deposition found in the TM 
tissue of glaucomatous eyes (right) decreases spaces between adjacent beams, impeding 
drainage of AH (4).  Adapted from Lutjen-Drecoll E., & Rohen JW, eds, (1996). Morphology of 
Aqueous Outflow Pathways in Normal and Glaucomatous Eyes. 2nd ed. St. Louis: Mosby.   
Additional changes to the structure of the TM, with implications for efficient 
function, have been reported.  Cellularity of the TM tissue decreases with age, 
such that TM cells detach from the ECM beams and fusion of adjacent cell-less 
beams increases (26-28). This further increases resistance to aqueous outflow.  
Similarly analysis of POAG patient samples, showed that while there are no 
differences in the rate of loss of cellularity between POAG patients and unaffected 
controls, the patients with POAG had lower levels of TM cells overall (27).  
Specifically, the TM of POAG patients was found to have thickened beams and an 
excess of collagen fibers, in addition to decreased cell number in the uveal TM.  
Finally the same study concluded that the lining of Schlemm’s canal had indeed 
demonstrated increased ECM product deposition (28). 
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1.3 Glaucoma 
1.3.1 Epidemiology and Classification 
Age-related blinding ocular disease affects more than 4 million Canadians and in 
2007 cost the Canadian healthcare system $16 billion (2). Glaucoma, a 
progressive optic neuropathy with pathology occurring in the anterior segment of 
the eye, is currently listed as the second leading cause of irreversible blindness 
worldwide (1).   As the baby-boomer generation progresses into retirement, an 
unprecedented percentage of the population will be over the age of 65.  As a direct 
consequence, the overall burden of disease will increase substantially from the 
nearly 70 million currently affected, with global projections estimating upwards of 
80 million people to be affected with glaucoma by 2020 (1).  The burden of 
glaucoma is not restricted to the financial cost of treatments and surgeries.  The 
impact of vision loss deeply affects the quality of life of patients, their caregivers, 
and family members (2, 29). 
Two main types of glaucoma can be classified according to etiology: primary angle-
closure glaucoma and primary open-angle glaucoma (POAG).  Both types occur 
when AH is not able to drain from the anterior segment of the eye.  Increased 
resistance to AH outflow leads to increased IOP resulting in optic nerve 
degeneration and blindness (29, 30). Primary angle-closure glaucoma involves 
forward movement of the iris that greatly impedes access to the trabecular 
meshwork (TM), interfering with AH drainage.  Primary open-angle glaucoma 
occurs when aqueous outflow is impeded at the level of the TM due to tissue 
dysfunction.  POAG is the most common type of glaucoma, affecting nearly 74% 
of all glaucoma patients (1).  Secondary glaucoma can also occur, typically 
manifesting after ocular trauma and often as a result of prolonged corticosteroid 
use (30). 
1.3.2 Pathogenesis 
Although the pathogenesis of glaucoma has yet to be elucidated, there are multiple 
theories relating to disease development and progression.  Since POAG is 
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complex and multifactorial, it is difficult to determine direct causation and it is more 
likely that effects are due to a complex interplay of many factors.  Specifically, both 
a vascular and a mechanical theory exist to suggest a mechanism by which 
glaucomatous blindness occurs (31-33).  The vascular theory suggests that 
damage to the retinal ganglion cells (RGCs) of the optic nerve occurs due to 
decreased blood flow to the area as a result of increased IOP (6, 31-33).  The 
RGCs then become ischemic and are eventually damaged beyond repair, resulting 
in blindness.  Alternatively, the mechanical theory suggests that RGCs are 
irreversibly injured by the mechanical force to which they are subjected when a 
patient has elevated IOP (29, 30, 34).  The most likely scenario includes 
combinatory effects of both, such that IOP increases are able to disrupt vascular 
dynamics to decrease blood flow and viability of RGCs.   
1.3.3 Risk Factors 
Common risk factors for POAG include advanced age, African or Hispanic 
ancestry, family history of POAG, a high degree of myopia, and elevated IOP.  
While mostly affecting those 65 years of age and older, the prevalence of POAG 
has been shown to increase steadily with each decade after the age of 40 (35).  
POAG shows a strong racial predilection.  This effect is most prominent among 
patients of African and Hispanic descent, with rates of blindness due to glaucoma 
reported to be six times higher than Caucasian glaucoma patients in the United 
States (29).  Those with POAG are twice as likely to report a first-degree relative 
with a condition in comparison to those not affected by POAG (29, 30). High 
myopes are also at risk for POAG, as a lack of structural support from the sclera 
posteriorly makes the optic nerve more susceptible to damage (29, 32).  Finally, 
elevated IOP is not only a risk factor for POAG, but also the most notable hallmark 
of the disease.  Normal values for IOP range from 10-21 mmHg, with 
measurements above 21 mmHg considered to be pathologically high (29, 30).  As 
IOP remains the only modifiable risk factor, clinical interventions are made with the 
intent to reduce IOP and prevent further damage to the optic nerve and resultant 
blindness.  Studies have shown that a mean reduction of IOP by 25% considerably 
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slows progression of the disease, when considering vision loss as an end-point 
(29). 
1.3.4 Diagnosis and Treatment Options 
Since the development of POAG is poorly understood, few preventative measures 
(other than increased vigilance with screening and prophylactic reduction of IOP) 
are available to guard against the disease.  Currently all treatment paradigms 
initially take a reactive approach aiming primarily to decrease IOP (the only 
modifiable risk factor), and subsequently take more aggressive approaches such 
as surgery to increase outflow facility.  Patients labeled “glaucoma suspects” are 
referred to an ophthalmologist and a diagnosis of clinical glaucoma is made upon 
confirmation of at least two of the following findings: elevated IOP (above 21mmHg 
or in the upper limit of normal), increased cup to disc ratio of the optic nerve, or 
changes to the retinal nerve fiber layer, and decreased peripheral field of vision 
(29, 30).  Due to the nature of the disease, vision loss progresses gradually such 
that early loss of vision is imperceptible to the patient.  In fact, COS guidelines 
estimate that up to 50% of those with glaucoma are unaware of the condition (29).   
Treatment options include pharmacological eye drops and surgery to reduce IOP 
and facilitate AH drainage. Prescription eye drops are often the first choice to 
control IOP.  Prostaglandins and prostaglandin analogs assist with fluid drainage, 
whereas beta-blockers can be prescribed to decrease fluid production (29, 30).  
Selective laser trabeculoplasty (SLT) is recommended for patients unable to 
successfully control IOP with eye drops alone (29, 30).  During an SLT procedure, 
a laser is aimed at the TM tissue, which improves the function of the TM and 
increases aqueous outflow.  While SLT is usually successful, the effects are not 
permanent as the factors contributing to fibrosis of the TM are still present, and 
thus repeat SLT is often not useful.  Finally, conventional surgery is performed as 
a last resort for patients who have been unresponsive to, or whose glaucoma has 
not been adequately controlled by previous measures (29, 30).  A trabeculectomy 
is performed in which part of the TM tissue is removed and an opening in the sclera 
of the eye is created to facilitate AH drainage.  Outcomes of trabeculectomy are 
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typically positive (80-90% effective at decreasing IOP (30)) and side-effects are 
usually treatable, although this procedure addresses the disease late in its 
progression.  Procedures to insert stents as artificial means of drainage, can also 
be useful (29).  Ultimately, there have not been any new developments in causal 
glaucoma treatments during the past two decades, despite an increasing number 
of glaucoma patients and a clear need for treatments to do more than simply 
assuage the symptoms.  Most importantly, current treatments focus on reducing 
IOP while none are specifically targeted to treat and prevent TM tissue dysfunction. 
1.4 Fibrosis 
Fibrosis is an accumulation of excess extracellular matrix (ECM) that can result in 
scarring.  The ECM is composed of many different components, including 
proteoglycans, structural fibers, and adhesion molecules; however, collagen and 
fibronectin are the most abundant and the most commonly implicated in disease 
(14).  When present in excess quantities, especially with an increase of structural 
fibers, excess ECM can result in tissue dysfunction.  The effects of increased ECM 
deposition causing organ failure and, often, death have been highly documented 
in a myriad of organs, including cardiac myofibroblasts, kidney, lung, and skin (7, 
36-39) highlighting decreases in normal tissue function as a result.  
The basic mechanisms for ECM maintenance and remodeling involve a balance 
between factors which promote ECM deposition, and factors which promote the 
degradation of existing ECM.  Growth factors are common inducers of ECM 
deposition, whereas proteases are common ECM remodeling proteins.  Primarily, 
increased matrix metalloproteinase (MMP) expression and activity acts to break 
down the ECM.  The action of MMPs can be regulated by the expression of tissue 
inhibitors of metalloproteinases (TIMPs) and other tissue specific protease 
inhibitors (40, 41).  Common MMPs found to act upon the ECM of TM cells are 
MMPs-1, -2, -13, and -14, with specific affinity for COL1 protein (40).  It has also 
been reported that a variety of MMPs are normally expressed in unstimulated TM 
cells supporting the theory that TM cells have a crucial role in remodeling the ECM 
(40).   
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Furthermore, a study of hTM cells stimulated with TGFβ2 revealed increased 
expression of the MMP-2 proform as well as increased expression of plasminogen 
activator inhibitor-1, an endothelial cell specific protease inhibitor (42).  The 
investigators found that plasminogen activator inhibitor-1 was acting to suppress 
activation of MMP-2 by maintaining MMP-2 in its proform, and therefore acting to 
inhibit ECM remodeling in the presence of TGFβ2 (42).   
ECM is normally remodeled in response to mechanical stretch in order to maintain 
efficient aqueous outflow.  Further importance is given to this role as upregulation 
of MMPs specific to COL1 occur after stimulation (particularly sustained exposure 
to increased pressure) (40).  MMPs-2, and -14 have also been shown to be 
upregulated in TM cells in response to stretch of the TM tissue due to increased 
IOP (41).  When the TM becomes fibrotic, cells may no longer be able to sense 
changes in pressure and may not respond appropriately resulting in further 
resistance to aqueous outflow (40).   
A fine regulatory balance between factors affecting ECM deposition and turnover 
must be achieved to prevent fibrosis and tissue dysfunction.  However, since pro-
fibrotic growth factors are required for normal cellular function, targets downstream 
of growth factor signaling have the highest potential to successfully attenuate and 
prevent fibrosis. 
1.5 Transforming Growth Factor β 
Many factors are able to induce ECM deposition, and one such factor is 
transforming growth factor-beta (TGFβ).  TGFβ is active in many different 
biological processes, among them cell differentiation, proliferation, migration, and 
survival (43-49).  TGFβ has also been identified as a key player in many disease 
processes including oncogenesis, autoimmunity, inflammation, and fibrosis (45, 
50-54). Particularly, TGFβ has long been implicated in the fibrosis of various 
tissues as well as multiple fibrotic conditions (55) including but not limited to renal 
and pulmonary fibrosis (39, 51).   
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TGFβs are secreted cytokines that belongs to the TGFβ superfamily (43, 44).  The 
latency-associated pro-region encodes a Latency Associated Peptide (LAP) that 
shields the protein to maintain an inactive state and assists in proper folding of the 
mature peptide.  The LAP must be enzymatically cleaved from the remaining C-
terminal sequence, for TGFβ maturation, activation, and binding to its receptor, 
TGFβ receptor (TGFβR) II (43, 44).  Upon binding to TGFβ, TGFβRII then 
dimerizes with, and phosphorylates, TGFβR I to initiate a signaling cascade.   
In mammalian cells TGFβ is found as three isoforms; TGFβ1, TGFβ2, and TGFβ3.  
Each of the three isoforms, while structurally similar, occupies a different niche 
function.  For example, levels of TGFβ1 have been found to be elevated within the 
wound microenvironment (56).  TGFβ1 assists in would healing, but an increased 
amount can contribute to fibrosis (56).  In addition, TGFβ1 has been dually 
implicated in cancer progression and suppression of tumor growth (54).  TGFβ2 
has been shown to be present within the AH of the eye (5, 57, 58).  Conversely, 
TGFβ3 has been found to be highly expressed in fetal tissue and associated with 
in utero wound-healing without scar formation (59).  Although the functions of the 
three TGFβ isoforms may vary slightly according to cellular milieu, they are all 
activated and signal through TGFβRs in a similar manner.   
1.5.1 Ocular TGFβ 
We focus on the specific isoform TGFβ2, which is found to be significantly 
increased within the AH of POAG.  The average level of TGFβ2 in normal eyes is 
roughly 1.48ng/mL, with about 37% of the TGFβ2 in active form.  AH from the eyes 
of POAG patients, however, have an average concentration of 2.70ng/mL, up to 
60.84% of which is activated at any given time (5, 57).  In contrast, a recent 
investigation of TGFβ1 expression in human aqueous humor found total levels to 
be less than 0.1pg/mL in both control and POAG samples (60).  Due to the low 
expression values, samples were not further analyzed to determine the ratio of 
mature to latent forms of TGFβ1 (60). 
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Expanding on previous work, Tripathi and colleagues found porcine TM cells to 
express the TGFβ2 mRNA, suggesting they are capable of producing the cytokine 
(58).  Subsequent investigation showed that indeed TGFβ2 is secreted into the 
medium of porcine TM cells in culture, and that all secreted TGFβ2 is in latent form 
(58).  Furthermore, hTM cells have also been found to express the TGFβ receptor, 
both TGFβRI and TGFβRII, required for binding of TGFβ and activation of the 
signaling cascade (61).  Dual paracrine (58) and autocrine (61) modes of TGFβ 
signaling are present in TM cells as evidenced by their ability to produce and 
respond to their own TGFβ isoforms.   
Physiologically, TGFβ2 is required to maintain the immune privileged status of the 
eye and is essential for normal ocular wound healing by stimulating production and 
deposition of ECM (62).  TGFβ accomplishes its role by activating multiple 
signaling cascades within the cell (43, 50, 55, 63-67).   
1.5.2 TGFβ Signaling 
Canonical TGFβ signaling involves intracellular signal transduction proteins, 
commonly known as SMAD effector proteins.  The signaling cascade initiated by 
TGFβ binding to its receptor results in transphosphorylation of TGFβRI by 
TGFβRII.  TGFβRI phosphorylation of SMAD2 and SMAD3 is facilitated by SMAD 
anchor for receptor activation (SERA), which is able to bind to the plasma 
membrane via phosphatidylinositols (43, 44, 68).  Next, pSMAD2/3 recruits the 
signal transducer SMAD4 and the complex then translocates to the nucleus.  In 
combination with transcription factors, the SMAD2/3/4 complex is able to modulate 
transcription of various genes, including upregulation of COL1A1 mRNA.  Inhibitory 
SMADs, particularly SMAD7, are induced as part of a negative feedback loop to 
counteract the effects of TGFβ signaling (43).  SMAD7 is able to block TGFβ 
signaling by recruiting ubiquitin protein ligases to degrade the receptors and inhibit 
propagation of the TGFβ signal (44) (Figure 1.5.1).  
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Figure 1.5.1 Canonical TGFβ signaling. 
(A) Binding of TGFβ to TGFβRs causes phosphorylation of SMADs 2/3.  Phosphorylated SMADs 
2/3 recruit SMAD4 and form a complex of SMADs 2/3/4.  (B) The SMAD complex translocates to 
the nucleus where it interacts with transcription factors (TF) to modulate gene transcription.  
SMAD7 is induced by SMAD3 to inhibit propagation of the TGFβ signal (43, 44, 68). 
A more recent report outlines the importance of TGFβR trafficking for signal 
propagation and receptor turn-over (68).  Internalization of TGFβRs in complex 
with SMAD7 occurs via the binding of caveolin-1 to TGFβRI (68).  TGFβRs in 
caveolin-positive vesicles are then degraded in a ubiquitin-dependent manner 
(68).  Alternatively, TGFβRs internalized in clathrin-coated pits, which form early 
endosomes, are sequestered from caveolin endosomes to prevent degradation 
(68).  Endosome sequestering of TGFβRs may promote TGFβ signaling in more 
than one way, since phosphatidylinositols, a common substrate for many kinases 
and phosphatases, are enriched to the endosome (68).   
Conversely, non-canonical signaling pathways involving AKT and FAK, which are 
responsible for controlling cell proliferation, migration, survival and ECM 
deposition, are inducible by TGFβ (43, 50, 63, 64, 69). The mechanisms of non-
canonical TGFβ signaling are discussed in detail in Chapters 3 and 4. 
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Pathologically increased overall TGFβ levels, and increased proportions of active 
TGFβ isoforms can induce fibrotic changes.  Most importantly, increased levels of 
TGFβ2 in the eyes of POAG patients correlate to increased ECM deposition within 
the TM (3, 4).  Considering the function of the TM tissue and how tissue stiffness 
would negatively affect performance, fibrosis of the TM with decreased AH 
drainage is a reasonable mechanism to account for increased IOP.   
1.6 Phosphatase and Tensin Homolog 
1.6.1 PTEN Structure and Function 
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) has recently 
emerged as a regulator of fibrosis.  PTEN is a member of the protein tyrosine 
phosphatase family, and exhibits dual protein and phospholipid phosphatase 
activity (70).  Alternatively, the gene that encodes PTEN is known as mutated in 
multiple advanced cancers 1 (MMAC1), and TGFβ regulated and epithelial cell 
enriched phosphatase 1 (TEP 1).  
The protein structure of PTEN is categorized into 3 major domains: a phosphatase 
region; a C2 domain; and a C-terminus (70).  The active site of PTEN resides in 
the phosphatase region allowing for catalytic activity.  The C2 domain is implicated 
in the intracellular localization of PTEN.  When PTEN is bound to the plasma 
membrane it exhibits enhanced catalytic activity (70).  The tail region contains 
various residues which can be modified by post-translational addition of functional 
groups, including glycosylation, ubiquitination, and phosphorylation (71).  Several 
residues within the tail region can be phosphorylated, with phosphorylation 
patterns able to regulate the enzymatic ability and stability of PTEN (71). Overall, 
the stability, activity, and localization of PTEN within the cell are controlled by post-
translational modifications.   
The main enzymatic function of PTEN is its phospholipid phosphatase activity.  By 
dephosphorylating phosphatidylinositol-3 (PIP3) into phosphatidylinositol-2 
(PIP2), PTEN directly antagonizes phosphoinositide-3 kinase (PI3K) activity (70). 
PIP3 is required for the activation of the AKT pathway, promoting cell growth, 
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proliferation, and survival.  Therefore, by negatively regulating AKT, PTEN is 
responsible for cell cycle regulation, controlling cell growth, and initiating 
apoptosis. 
Finally, PTEN also exhibits protein phosphatase activity by removing phosphate 
groups from tyrosine residues.  Most importantly, two major targets involved in 
prominent cell signaling pathways are implicated with PTEN’s protein phosphatase 
activity, including FAK (focal adhesion kinase) and Src homology 2 domain 
containing transforming protein (Shc).  PTEN removes phosphate groups from 
tyrosine residues on the activated FAK molecule to decrease FAK signaling for cell 
migration and other parts of cell metabolism related to cytoskeleton (72, 73).  Shc 
is implicated early in the mitogen-associated protein (MAP) kinase pathway that 
responds to various extracellular signals, including cellular stretch (72, 73).   
Regulatory post-translational modifications in the C-terminal region are primarily 
phosphorylation events (70).  Combinations of phosphorylation at multiple 
residues affect enzymatic activity by either increasing stability to decrease activity, 
or decreasing stability and increasing activity.  Such combinations of 
phosphorylation are able to induce changes in conformation that affect cellular 
localization. PTEN’s binding to the plasma membrane is crucial for enzymatic 
activity as PTEN is in closer proximity to its substrate PIP3.  When localized to the 
cytosol, PTEN is less active (70).  Analysis of PTEN activity is therefore more 
informative than consideration of expression levels alone.  The specific effects of 
C-terminal phosphorylation are further discussed in Chapters 3, 4, and 5.   
Phosphorylation of the C2 domain has also been reported, mostly by Src/RAK and 
ROCK in terms of stabilizing the molecule and promoting additional 
phosphorylation (70).  Ubiquitination of PTEN is also observed in the C2 domain 
at lysine residues 13 and 289, dictating cellular stability and localization (70).  With 
increased ubiquitination of PTEN, stability and activity decrease, but localization 
to the nucleus increases, where it is able to signal for apoptosis (70, 74). 
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Recent reports have also found evidence of a secreted version of PTEN.  
Discovery of a translational variant of PTEN, which is more than twice as long as 
the normal PTEN protein, yielded the classification of PTEN-Long (75).  The 
PTEN-Long protein is a membrane-permeable lipid phosphatase.  Secreted 
PTEN-Long can enter neighboring cells where it seems to function similarly to 
normal PTEN by restoring function and inhibiting the PI3K/AKT pathway in cells 
that have compromised, or lost, PTEN function (75). 
Finally, emerging work shows that PTEN has a role in the modulation of ECM 
deposition.  Specifically, increased PTEN expression decreases collagen 
deposition in the ECM, whereas decreased PTEN expression allows for an 
increase in collagen deposition (7, 38, 39).  Most importantly, loss of PTEN causes 
fibrosis of dermal fibroblasts and lung fibroblasts in a mouse knockout model of 
Pten (7, 8).  The specific function of PTEN in the TM of normal and glaucomatous 
eyes remains to be elucidated. 
1.7 Hypothesis and Objectives 
1.7.1 Hypothesis 
We hypothesize that TGFβ2 modulates the deposition of ECM in the TM by 
regulating the expression and activity of PTEN protein, ultimately affecting 
aqueous outflow. 
1.7.2 Objectives 
1. To investigate the modulation of PTEN by TGFβ2 by studying PTEN mRNA 
expression, PTEN protein expression, and phosphorylation of PTEN. 
2. To investigate the regulation of PTEN by studying the cell signaling 
mechanisms involved with the use of small molecule inhibitors of cell 
signaling pathways. 
3. To investigate the functional role of PTEN in ECM regulation by inhibiting 
PTEN activity and by altering expression of PTEN. 
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Chapter 2  
2 Materials and Methods 
2.1 Human Donor Trabecular Meshwork Cell Culture 
Human trabecular meshwork cells (hTM cells) (ScienCell, Carlsbad, CA, US) were 
cultured in DMEM (Life Technologies, Burlington, ON, CAN) supplemented with 
10% FBS and 1% P/S (Life Technologies), and maintained at 37ᵒC and 5% CO2 
in a humidified incubator.  Cells were used at passage 4-5.  All experiments were 
performed on 6-well tissue culture plates; either Nunc plastic (ThermoFisher 
Scientific, Waltham, MA, US), Bioflex ™ pronectin-coated (Flexcell International 
Corporation, Burlington, NC, US) or Bioflex ™ collagen type 1-coated (Flexcell).  
Once cells reached 90% confluency, the medium was replaced with DMEM 
supplemented with 0.5% FBS and 1% P/S (Life Technologies).  After 5 hours cells 
were pretreated with specific small molecule inhibitors, either LY294002 (Selleck 
Chemicals), PP2 (Selleck Chemicals), SB431542 (Tocris Bioscience, Minneapolis, 
MN, US), VO-OHpic (Tocris Biosciences), or ZSTK474 (Selleck Chemicals) for one 
hour.  Cells were then treated with either vehicle, human recombinant TGFβ2 
(R&D Systems Inc), inhibitor alone, or a combination of TGFβ2 and inhibitor.  
Initially, concentrations of inhibitors were chosen based on commonly used 
concentrations cited in the literature.  Concentrations were adjusted experimentally 
based on response of hTM cells.  All treatments and concentrations used are listed 
in Table 2.1. 
Table 2.1.1. List of Treatments Used for Cell Culture. 
Treatment 
Concentration
s 
Tested 
Concentration
s 
Used 
Function Supplier 
Human 
Recombinant 
TGFβ2 
1ng/mL 
5ng/mL 
10ng/mL 
1ng/mL 
5ng/mL 
10ng/mL 
Growth 
factor 
R&D Systems 
Inc, (302-B2-
002) 
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SB431542 
12µM 
20µM 
20µM 
ALK5 
(TGFβ 
Receptor) 
inhibitor 
Tocris 
Bioscience 
(1614) 
LY294002 
10µM 
20µM 
30 µM 
20µM 
30 µM 
PI3K 
inhibitor 
PI3Kα/δ/β 
Selleck 
Chemicals 
(S1105) 
ZSTK474 
2µM 
5µM 
2µM 
5µM 
PI3K 
inhibitor 
class I 
PI3K 
isoforms 
Selleck 
Chemicals 
(S1072) 
PP2 
8 µM 
10µM 
16 µM 
20µM 
30 µM 
10µM 
20µM 
Src 
inhibitor 
Selleck 
Chemicals 
(S7008) 
VO-OHpic 
0.25µM 
0.5µM 
1µM 
2.5µM 
5µM 
0.25µM 
0.5µM 
1µM 
2.5µM 
5µM 
PTEN 
inhibitor 
Tocris 
Bioscience 
(3591) 
     
2.2 Cellular Transfection 
hTM cells were maintained as described above. After plating on to Nunc plastic 6-
well tissue culture plates (ThermoFisher Scientific), hTM cells were left to grow 
until slightly past confluent. At this point the medium in each well was replaced with 
2mL DMEM supplemented with 0.5% FBS (Life Technologies).  After 6 hours hTM 
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cells were transfected with 1.0µg DNA (either pcDNA3.1 + IRES GFP, ePTEN, or 
C124S PTEN; further discussed in Chapter 5) using the PolyMag Neo 
Magnetofection Kit (OZ Biosciences INC, CA, USA).  1.0µg of each type of DNA 
was dissolved into 200µL serum-free DMEM and then added to 1.0µL transfection 
reagent.  The complex was incubated at room temperature for 20 minutes before 
adding drop-wise to the hTM cells.  The 6-well plate was placed atop the PolyMag 
Neo magnet inside the incubator set at 37ᵒC and 5% CO2 for 4-5 minutes.  Medium 
was removed immediately following transfection and replaced with 3mL DMEM 
supplemented with 0.5% FBS (Life Technologies).  After 20 hours, culture medium 
was refreshed and select hTM cells were treated with human recombinant 5ng/mL 
TGFβ2 (R&D Systems) dissolved in DMEM with 0.5% FBS (Life Technologies). 
2.2.1 Subcloning and Purification of Bacterial Plasmids 
Competent DH5α Escherichia coli (E. coli) (Life Technologies) were transformed 
as per supplier’s protocol, with mutated PTEN DNA (ePTEN and C124SV) kindly 
donated by Dr. Miho Iijima (Department of Cell Biology at the John Hopkins School 
of Medicine, Baltimore, MD, US) and control vector pcDNA3.1 IRES GFP 
(Addgene, Cambridge, MA, US).  Transformed E. coli were plated onto LB-agar 
plates with 100µg/mL ampicillin (Amp).  Individual colonies were isolated and 
allowed to grow in 5mL of LB supplemented with 100µg/mL Amp for 8 hours at 37 
ºC.  The culture was then diluted 1:500 in 50mL LB supplemented with 100µg/mL 
Amp, and incubated at 37 ºC for 14 hours.  Plasmids were then purified using the 
ZymoPURE ™ Plasmid Midiprep Kit (Zymo Research Corporation, Irvine, CA, US). 
2.3 RNA Isolation and RT-PCR 
RNA was isolated using the RNeasy RNA extraction kit (Qiagen, Mississauga, ON, 
CAN) and quantified (Nanodrop 1000, ThermoFisher Scientific).  Twenty five ng of 
RNA was used in each reaction of real-time polymerase chain reaction (RT-PCR). 
One-step RT-qPCR master mix (qScript XLT One-step RT-qPCR ToughMix, ROX; 
Quanta Biosciences, Beverly, MA, USA) was used along with TaqMan Assay-on-
Demand primers (Applied Biosystems, Life Technologies) for PTEN and COL1A1.  
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Samples were run in triplicate and sequences were detected with ABI Prism 
7900HT (Applied Biosystems).  Target mRNA expression values were normalized 
to Euk 18S rRNA, and further analyzed using the ΔΔCt method to determine fold 
change. 
2.4 Protein Isolation and Immunoblotting 
Cells were lysed in Pierce IP lysis buffer (ThermoFisher Scientific) supplemented 
with EDTA and PI cocktail (ThermoFisher Scientific) after 24 and 48 hours.  Total 
protein concentration estimation was performed using the Micro BCA Protein 
Assay Kit (ThermoFisher Scientific).  Equal amounts of protein (10-12µg) from 
each sample were prepared and run through SDS-PAGE, then transferred to a 
nitrocellulose membrane. Membranes were blocked in a solution of 5% BSA 
(Sigma, St. Louis, MO, US) dissolved in Tris-buffered saline (TBS) with 0.01% 
Tween-20 (TBS-T) for 1 hour, and incubated overnight at 4ºC with anti-PTEN rabbit 
pAb (AF847) (1:2000; R&D Systems, Inc), anti-phosphoPTEN Ser380-Thr382/383 
rabbit mAb (44A7) (1:2000; Cell Signaling Technologies, Danvers, MA, US), anti-
AKT (pan) rabbit mAb (C67E7) (1:2000; Cell Signaling Technologies), anti-
phosphoAKT Ser473 (D9E XP) rabbit mAb (1:2000; Cell Signaling Technologies), 
anti-collagen type 1 rabbit mAb (EPR7785) (1:2000; Abcam, Cambridge, UK) and 
anti-GAPDH mouse mAb (9B3: sc-66163) (1:3000; Santa Cruz Biotechnology, 
Santa Cruz, CA, US).  Blots were washed 3 times, for 5 minutes each, with TBS-
T then incubated for 1 hour at room temperature with anti-rabbit IgG horseradish 
peroxidase conjugate (1:3000; BioRad, Mississauga, ON, CAN) or anti-mouse IgG 
horseradish peroxidase conjugate (1:3000; BioRad) secondary antibodies.  Blots 
were imaged using an ECL detection method (WesternBright ECL HRP substrate 
(Advansta, Menlo Park, CA, US) and the Chemi Genius 2 Bio Imaging System 
(Syngene, Fredrick, MD, US)) to visualize proteins.  Blots were stripped of bound 
antibodies using Restore Western Blotting Stripping Buffer (ThermoFisher 
Scientific), and then reprobed (to a maximum of two additional times) as described 
above.  Residual signal was assessed between re-probing and stripping conditions 
were optimized to ensure adequate removal of primary and secondary antibodies. 
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Densitometric analysis of western blot bands was performed using ImageJ 
software. 
Table 2.4.1. List of Antibodies Used for Immunoblotting. 
Antibody Concentration Supplier 
Anti-PTEN rabbit pAb 1:2000 
R&D Systems Inc, 
(AF847) 
Anti-phosphoPTEN 
(Ser380/Thr382/383) rabbit 
mAb 
1:2000 
Cell Signaling 
Technologies 
(44A7) 
Anti-AKT (pan) rabbit mAb 1:2000 
Cell Signaling 
Technologies 
(C67E7) 
Anti-phosphoAKT (Ser473) 
rabbit mAb 
1:2000 
Cell Signaling 
Technologies 
(D9EXP) 
Anti-collagen type I rabbit mAb 1:2000 
Abcam 
(EPR7785) 
Anti-FAK rabbit pAb 1:2000 
ThermoFisher 
Scientific 
(PA5-16676) 
Anti-phosphoFAK (Tyr397) 
rabbit mAb 
1:2000 
Cell Signaling 
Technologies 
(D20B1) 
Anti-GAPDH mouse mAb 1:3000 
Santa Cruz 
Biotechnology      
(9B3:sc-66163) 
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Anti-rabbit IgG Horseradish 
Peroxidase Conjugate 
1:3000 
BioRad 
(170-6515) 
Anti-mouse IgG Horseradish 
Peroxidase Conjugate 
1:3000 
BioRad 
(170-6516) 
2.5 Statistical Analysis 
Data from RT-PCR experiments are represented as relative fold change in 
comparison to internal control (Euk 18S) and control treatment.  Two-way ANOVA 
was used to determine whether the difference in means between treatment groups 
was statistically significant.  Bonferroni’s post-hoc test was then applied to 
determine the source of statistically significant effects detected by ANOVA. Protein 
expression levels were normalized to the internal control (GAPDH) for each protein 
sample, and then compared to the control level of expression for each donor to 
determine the relative fold change. One-way ANOVA was used to determine 
whether the means of different treatment groups were statistically significant.  
Tukey’s post hoc test was applied to determine the source of statistical significance 
detected by ANOVA.  Differences were considered statistically significant when p< 
0.05.  GraphPad Prism software (version 6.0, GraphPad Software, San Diego, CA) 
was used for all statistical analyses. 
23 
 
Chapter 3 
3 Modulation of PTEN by TGFβ2 
3.1 Rationale 
In this chapter, we examine the effects of TGFβ2 on hTM cells with emphasis on 
PTEN and production of the ECM protein COL1.  The pro-fibrotic role of TGFβ has 
been widely documented in multiple organ systems, including the lungs, liver, and 
kidneys (43, 50, 51, 76).  Furthermore, it has been established that elevated levels 
of TGFβ2 are present in the AH of POAG patients (5).   Similarly, recent studies of 
PTEN support its role in fibrosis (39, 51, 52, 77, 78). While some mechanisms for 
their interaction have been suggested in other model systems (39, 51, 52, 77, 78), 
further work is required to determine how TGFβ regulates PTEN in hTM cells.  
Moreover, regulatory control mechanisms are also of interest, particularly 
posttranslational phosphorylation of PTEN as it positively influences protein 
stability and negatively affects enzymatic activity (70). 
We aim to examine PTEN and COL1A1 mRNA expression and PTEN and COL1 
protein expression in hTM cells to characterize the pro-fibrotic effects induced by 
TGFβ2. 
3.2 Background 
TGFβ2 is part of the TGFβ superfamily, which is known to induce fibrosis and 
remodeling of the ECM (43, 44).  Most importantly, TGFβ2 levels are significantly 
increased, with a greater ratio of active to latent TGFβ2 in the AH of glaucoma 
patients (5).  TGFβ2 induces fibrosis of the TM tissue by inducing increases in 
expression of ECM proteins, including fibronectin (25), collagen type IV (79), and 
COL1 (80).  Of particular interest is COL1, a component of the TM tissue (14, 17), 
and a marker of fibrotic conditions (55, 81).  In fact, a mouse model of collagenase-
resistant COL1 was shown to exhibit hallmarks of fibrosis and glaucoma with 
increased age (82, 83).  As mutant COL1 was not degraded or remodeled, 
expression of COL1 increased throughout the anterior chamber of the eye (82).  
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Anterior chamber fibrosis was accompanied by significant increases in IOP as the 
mice aged (82, 83). 
To identify a mechanism by which canonical TGFβ signaling results in COL1 
deposition, one study examined anterior segment fibrosis in secreted protein rich 
in acidic and cysteine (SPARC)-null mice (79).  SPARC regulates the ECM, as 
overexpression of SPARC induces TM fibrosis in experiments using human 
cadaveric eyes (84).  Using SPARC-null mice, it was determined that TGFβ2 is 
able to increase COL1 expression through a SMAD-independent pathway, 
primarily through the induction of connective tissue growth factor (79). 
Finally, TM cells secrete their own TGFβ2 in vivo which could contribute to fibrosis 
(24, 58).  The ability of cultured TM cells to produce and secrete TGFβ2 is 
maintained in in vitro experiments (58, 61).  We aim to characterize the effects of 
TGFβ2 on COL1 expression of hTM cells. 
It has been widely reported in the literature that TGFβ is able to suppress the 
expression of PTEN mRNA and PTEN protein levels in various disease models of 
hepatocarcinoma, pancreatic and colon cancer, as well as in renal and pulmonary 
fibrosis (39, 51, 52, 77, 78, 85).  These investigations detail a combination of post-
transcriptional and post-translational mechanisms by which TGFβ is able to 
suppress PTEN.   
Initially, TGFβ was shown to suppress PTEN mRNA and PTEN protein expression 
in a cell line of hepatocarcinoma.  Specifically, TGFβ increased degradation of the 
PTEN transcript in a post-transcriptional mechanism of suppression (85).  The 
same study found decreases in total PTEN protein subsequent to TGFβ treatment, 
which occurred at a rate that could not be explained by increased turnover of the 
PTEN transcript.  Blockade of the ubiquitin-proteasome pathway rescued PTEN 
protein levels, suggesting TGFβ is also able to control PTEN expression post-
translationally by ubiquitination and degradation (85).   
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Investigation of a pancreatic cancer model has revealed that TGFβ has a similar 
effect on PTEN expression.  SMAD4-null pancreatic cancer cells were shown to 
have decreased PTEN protein and PTEN mRNA expression subsequent to 
treatment with TGFβ (77).  The mechanism of control in these cells occurs at the 
transcriptional level as TGFβ was able to increase activity of the transcription factor 
NF-κB to decrease transcription of the PTEN gene.  When treated with TGFβ in 
the presence of an NF-κB super-repressor, sequestering NF-κB in the cytoplasm, 
PTEN mRNA and PTEN protein expression was similar to the baseline expressed 
in control cells untreated with TGFβ.  Overexpression of SMAD4 had a similar 
effect to cytoplasmic sequestering of NF-κB, decreasing NF-κB activity even with 
TGFβ treatment. Since NF-κB activity increased after addition of TGFβ in SMAD4-
null cells, with further increases in NF-κB activity observed in cells that had 
conditional knock-outs of SMAD2 and SMAD3, the transcriptional mechanism of 
PTEN repression utilizes the non-canonical TGFβ signaling pathway (77).  
In addition, a recent study on SMAD4-null colon cancer cells reported TGFβ to 
decrease PTEN expression through increased tyrosine phosphorylation and 
activation of PI3K (52).  Here, regulation of PTEN also involves non-canonical 
TGFβ signaling.  The investigators suggested total PTEN protein was decreased 
by a combination of suppressed PTEN gene transcription and increased PTEN 
protein degradation subsequent to PI3K activation (52).  
Investigations of fibrotic conditions reveal similar results, characterizing an inverse 
relationship between TGFβ and PTEN expression. Increased TGFβ signaling 
induced after acute kidney injury caused a loss of PTEN protein in a subset of 
proximal tubule epithelial cells, resulting in renal fibrosis (51).  Rescue of PTEN 
expression by inhibiting TGFβ-signaling was able to decrease fibrosis (51).  A 
similar model of TGFβ-induced fibrosis in mesangial cells revealed the mechanism 
of PTEN downregulation to occur post-transcriptionally (78).  TGFβ induced 
expression of microRNAs 216a and 217, which bind the PTEN transcript to prevent 
translation (78).  Translation of PTEN mRNA resumed following inhibition of these 
microRNAs, restoring PTEN protein expression (78).  Furthermore, a study of 
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idiopathic pulmonary fibrosis discovered significantly decreased Pten mRNA and 
protein expression in fibrotic lung fibroblasts (39).  Overexpression of Pten was 
found to be sufficient to reduce the fibrotic phenotype (primarily collagen 
deposition) of lung myofibroblasts treated with TGFβ in a subsequent study (39).  
In the context of these findings, we aim to characterize the effects of TGFβ2 on 
PTEN mRNA and PTEN protein expression of hTM cells. 
Finally, previous studies have shown that PTEN is post-translationally modified by 
many different molecules within the cell (70, 71).  The most common and most 
reported upon modification is phosphorylation, particularly in the C-terminal region.  
Specifically, multiple studies have reported a triplicate site within the tail region of 
PTEN that increase protein stability and decrease activity when all three amino 
acid residues are phosphorylated in tandem (70, 71).  This site is 
Ser380/Thr382/383 (pPTEN).  The presence of these phosphorylation groups 
causes the tail region of PTEN to fold over the C2 domain.  In this “closed” 
conformation, the C2 domain is not able to bind the plasma membrane where 
PTEN’s substrate, PIP3, is in abundance.  pPTEN in its “closed” conformation then 
remains localized to the cytosol away from its substrate, and thus functionally 
inactive (Figure 3.2.1).  In our study of hTM cells, we aim to investigate expression 
of pPTEN (Ser380/Thr382/383) as a marker of enzymatic inactivity.  
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Figure 3.2.1. Open and Closed PTEN conformation. 
When PTEN is in open conformation, the C2 domain is able to bind to the plasma membrane.  
Binding to the plasma membrane increases enzymatic activity of PTEN because the enzyme is 
localized to its substrate PIP3.  When PTEN is phosphorylated on its tail region at residues Ser380, 
Thr382, and Thr383, PTEN adopts a closed conformation with the tail region folding over the C2 
domain.  The closed conformation of PTEN prevents binding to the plasma membrane binding and 
as a result PTEN is localized to the cytosol. 
3.3 Experimental Approach 
1. To determine the effects of TGFβ2 on COL1A1 and PTEN mRNA transcript 
levels, cultured hTM cells were treated with TGFβ2 (1ng/mL and 5ng/mL).  
RNA was extracted at 12 and 24 hours post-treatment and RT-PCR was 
performed. 
2. To determine the effects of TGFβ2 on COL1 and PTEN protein, hTM cells 
were cultured on pronectin-coated plates with increasing concentrations of 
TGFβ2 and effect of TGFβ2 further confirmed using an inhibitor to the TGFβ 
receptor.  Protein was isolated and immunoblotting was performed. 
3. To indirectly determine the relative activity of PTEN protein, immunoblots 
were analyzed for pPTEN (Ser380/Thr382/382). 
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3.4 Results 
3.4.1 TGFβ2 increases COL1A1 mRNA expression. 
Our first objective was to characterize the effects of active TGFβ2 on hTM cells.  
Here we treated hTM cells with TGFβ2 at 1ng/mL and 5ng/mL to cover a range of 
physiological to pathological levels of TGFβ2 present in the AH of glaucoma 
patients and measured changes in the mRNA transcript of COL1A1.  At 12 hours 
post-treatment with TGFβ2 1ng/mL we found a significant increase in the 
expression of the COL1A1 transcript (p<0.01).  Twenty four hours after treatment 
with TGFβ2 (1ng/mL and 5ng/mL) COL1A1 mRNA was significantly elevated 
(p<0.0001), roughly 4-fold in comparison to control (Figure 3.4.1).   
 
Figure 3.4.1 TGFβ2 increases COL1A1 mRNA expression. 
Real-time PCR results from hTM cells treated with TGFβ2 (1 or 5ng/mL).  RNA was extracted at 
12 and 24 hours. COL1A1 mRNA expression levels were normalized to Euk18s. A two-way ANOVA 
was used to test whether the means of treatment groups were statistically significant.  Bonferroni’s 
post-hoc was then applied to determine the source of statistical significance detected by ANOVA. 
**p<0.01, ****p<0.0001 in comparison to control; N=3. 
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3.4.2 TGFβ2 increases PTEN mRNA expression. 
We investigated the effects of TGFβ2 on PTEN transcript levels, with the 
expectation that PTEN mRNA would be decreased as reported in the literature at 
similar time points.  Instead, at 24 hours post-treatment with TGFβ2 5ng/mL, we 
observed a 2.15 fold increase in PTEN mRNA (statistically significant with p<0.05) 
(Figure 3.4.2).  Changes in the PTEN transcript induced by TGFβ2 after twelve 
hours were not significant. 
 
Figure 3.4.2 TGFβ2 increases PTEN mRNA expression. 
Real-time PCR results from hTM cells treated with TGFβ2 (1 or 5ng/mL).  RNA was extracted at 
12 and 24 hours.  PTEN mRNA expression levels were normalized to Euk18S. A two-way ANOVA 
was used to test whether the means of treatment groups were statistically significant.  Bonferroni’s 
post-hoc was then applied to determine the source of statistical significance detected by ANOVA.  
*p<0.05 in comparison to control; N=3. 
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3.4.3 COL1 protein expression after TGFβ2 treatment. 
Next, we wanted to verify that transcripts of genes upregulated by TGFβ2 were 
translated into functional proteins.  To confirm that the increased COL1A1 
transcripts were translated into COL1 protein we cultured hTM cells on pronectin-
coated plates using varying levels of TGFβ2 (1, 5, and 10ng/mL) and TGFβ 
receptor inhibitor SB431542 (20µM).  Protein expression of COL1 (Figure 3.4.3) 
after treatment with TGFβ2 is consistent with the upregulation of COL1A1 mRNA 
seen in Figure 3.4.1.  Addition of SB431542 decreased COL1 expression in 
comparison to TGFβ2-teated cells. COL1 expression was decreased expression 
below baseline levels at both 24 and 48 hours after the addition of SB431542.  
 
 
Figure 3.4.3 COL1 protein expression after TGFβ2 treatment. 
Immunoblots from hTM cells treated with increasing concentrations of TGFβ2 (1, 5, or 10ng/mL), 
and TGFβ receptor inhibitor SB431542 (20µM). Protein was extracted at 24 (A) and 48 hours (B).  
Immunoblots were probed with antibodies for COL1 and GAPDH. Western blot analysis shows 
increased COL1 expression with addition of  TGFβ2 in hTM cells.  N=1.   
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3.4.4 TGFβ2 increases PTEN protein expression and phosphorylation 
of PTEN. 
To verify that PTEN mRNA upregulated 2.15 fold by TGFβ2 was further translated 
into PTEN protein, we cultured hTM cells on pronectin-coated plates using varying 
levels of TGFβ2 (1, 5, and 10ng/mL) and TGFβ receptor inhibitor SB431542 (20 
µM).  We found significant increases in PTEN protein compared to controls at 24 
(p<0.05 for TGFβ2 10ng/mL) (Figure 3.4.4) and 48 hours (p<0.001 for TGFβ2 1, 
5, and 10ng/mL) (Figure 3.4.5) post-treatment.   Expression of PTEN protein was 
decreased upon pretreatment with SB431542, (significantly at 48 hours, p<0.001).   
Since TGFβ is repeatedly reported to suppress PTEN expression (39, 51, 52, 77, 
78, 85) we investigated post-translational modifications to reconcile our findings 
with those reported in the literature.  We found that although TGFβ2 increased 
PTEN protein, TGFβ2 also increased phosphorylation of PTEN at 
Ser380/Thr382/383, which renders the molecule functionally inactive (70).  
Increases in pPTEN were decreased upon pretreatment with SB431542.  Although 
TGFβ2 is able to induce significant increases in PTEN as shown over a range of 
concentrations, TGFβ2 can also increase phosphorylation of PTEN to inactivate 
the enzyme.  Finally, the ratio of pPTEN to PTEN did not vary according to 
treatment suggesting the changes to PTEN expression are accompanied by 
simultaneous changes to PTEN’s phosphorylation.  Results were replicated on 
plastic and COL1-coated plates at the same time points (Appendix A-B). 
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Figure 3.4.4 TGFβ2 increases PTEN protein expression and phosphorylation 
of PTEN at 24 hours. 
Immunoblots from hTM cells treated with increasing concentrations of TGFβ2 (1, 5, or 10ng/mL), 
and TGFβ receptor inhibitor SB431542 (20µM). Protein was extracted at 24 (A).  Immunoblots were 
probed with antibodies for PTEN, pPTEN (Ser380/Thr382/383), and GAPDH.  Levels of PTEN 
protein expression were increased with increasing amounts of TGFβ2 (1, 5, or 10ng/mL).  
Expression of PTEN protein was decreased upon pretreatment with SB431542 (20µM) prior to 
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addition of TGFβ2 5ng/mL.  Equivalent increases in phosphorylation of PTEN seen with increasing 
amounts of TGFβ2 (1, 5, or 10ng/mL).  Increases in PTEN phosphorylation were prevented by 
pretreatment with SB431542 (20µM) prior to addition of TGFβ2 5ng/mL. Densitometry for 24 PTEN 
(B), pPTEN (C), and relative pPTEN/PTEN (D) expression.  Data was analyzed using one-way 
ANOVA.  The source of statistical significance was determined by applying Tukey’s post-hoc test.  
(GraphPad Prism). *p<0.05; N=3. 
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Figure 3.4.5 TGFβ2 increases PTEN protein expression and phosphorylation 
of PTEN at 48 hours. 
Immunoblots from hTM cells treated with increasing concentrations of TGFβ2 (1, 5, or 10ng/mL), 
and TGFβ receptor inhibitor SB431542 (20µM). Protein was extracted at 48 hours (E).  
Immunoblots were probed with antibodies for PTEN, pPTEN (Ser380/Thr382/383), and GAPDH.  
Levels of PTEN protein expression were increased with increasing amounts of TGFβ2 (1, 5, or 
10ng/mL).  Expression of PTEN protein was decreased upon pretreatment with SB431542 (20µM) 
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prior to addition of TGFβ2 5ng/mL.  Similar increases in pPTEN were seen with increasing amounts 
of TGFβ2 (1, 5, or 10ng/mL).  Increases in PTEN phosphorylation were prevented by pretreatment 
with SB431542 (20µM) prior to addition of TGFβ2 5ng/mL. Densitometry for 24 PTEN (E), pPTEN 
(F), and relative pPTEN/PTEN (G) expression. Data was analyzed using one-way ANOVA.  The 
source of statistical significance was determined by applying Tukey’s post-hoc test (GraphPad 
Prism). *p<0.05, **p<0.01, ***p<0.001; N=3. 
3.4.5 Summary of Results 
1. TGFβ2 increased COL1A1 mRNA and COL1 protein. 
2. TGFβ2 increased PTEN mRNA and PTEN protein. 
3. TGFβ2 phosphorylated PTEN at Ser380/Thr382/383. 
3.5 Discussion 
These findings establish the response of hTM cells to TGFβ2 stimulation.  
Consistent with previous studies, we show that TGFβ2 induces ECM protein 
production in hTM cells.  To our surprise, we find that TGFβ2 is also able to induce 
increases in PTEN mRNA and PTEN protein, contrary to what has been reported 
in the literature.   
In finding that PTEN expression is increased under the influence of TGFβ2, and 
that total PTEN protein expression is correlated with decreased PTEN activity (as 
measured by increased pPTEN expression) we propose a novel mechanism by 
which TGFβ is able to regulate PTEN.  Here, we show the previously unreported 
effect of TGFβ2 increasing phosphorylation of PTEN as a means of inactivating 
PTEN’s enzymatic activity.  The Ser380/Thr382/383 phosphorylation is associated 
with decreased PIP3 enzymatic activity (86), such that phosphorylation at these 
sites causes the C-terminus of PTEN to fold over its C2 domain.  Once the C2 
domain is covered, PTEN is no longer able to bind to the plasma membrane and 
is then localized to the cytoplasm, away from its substrate PIP3 (70).  In this 
manner, PI3K signaling remains unopposed.  Up to this point, TGFβ has been 
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shown to only decrease expression of PTEN in various model systems (39, 51, 52, 
77, 78, 85).  
Decreased activity of PTEN by post-translational modification is consistent with the 
increased COL1 expression observed in our experiments. Even though the 
increase and subsequent inactivation of PTEN is a novel finding, the associated 
increase in COL1 is similar to other studies in which deletion of the Pten gene (7, 
8) or inhibition of PTEN activity causes an increase in COL1 deposition (39). 
One explanation for the novel regulatory mechanism of PTEN in hTM cells may be 
related to the nature of the TM cells and the niche role they occupy.  As discussed 
earlier, TM cells are subjected to severe stress, in the form of mechanical stretch 
caused by fluctuations in IOP.  TM cells must be able to quickly and efficiently 
respond to changes in stimuli to survive in this type of environment.  To facilitate 
rapid remodeling of the ECM, changes in PTEN activity can be controlled via 
phosphorylation.  The posttranslational mechanism of control would be favoured 
over a transcriptional control mechanism as it would allow for more rapid changes 
in activity.  Since activity-induced degradation of PTEN is reported to occur (86) 
the increase in PTEN protein observed with the concomitant increase in its 
phosphorylation may serve as a compensatory feedback mechanism.  
Phosphorylation can quickly inactivate PTEN while retaining the protein product in 
a readily available state, which allows for continuous ECM remodeling to facilitate 
adequate AH outflow.   
Alternatively, the phosphorylation of PTEN in response to TGFβ stimulation, may 
be attributed to a TGFβRII isoform present on TM cells (61).  Wordinger and 
colleagues identified mRNA of alternatively spliced TGFβRII isoforms in hTM cells 
(61).  They postulated that the transcripts were subsequently translated into 
functional receptors, building on previous investigations that confirmed the 
expression TGFβRs in porcine TM cells (87).  Binding of TGFβ to the TGFβR 
isoforms may slightly modify downstream signaling to give an altered response, 
although further investigations are required in this area. 
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Finally, we also observed decreases below baseline expression of COL1 protein 
after addition of SB431542.  This phenomenon can be explained by consideration 
of endogenous TGFβ2 expression of hTM cells.  Tripathi and colleagues 
determined that porcine TM cells in culture produce the mRNA transcript for 
TGFβ2, and also secrete TGFβ2 into the medium (58).  Secretion of endogenous 
TGFβ2 was found to peak at 48 hours, with secreted TGFβ2 measured to be 
20pg/mL (58).  An earlier investigation comparing expression levels of TGFβ in the 
aqueous humor of various animals found porcine aqueous humor to express 2.39 
times less TGFβ than human aqueous humor (490pg/mL compared to 1.17ng/mL) 
(88).  The authors note that more than 90% of the total TGFβ represented is the 
TGFβ2 isoform (88).  With careful consideration of these findings, it is likely that 
the hTM cells employed in our model secrete endogenous TGFβ2 at a rate greater 
than 20pg/mL, although further investigation is required for confirmation.  The 
decrease below baseline levels of COL1 protein with the addition of the TGFβR 
inhibitor could then be attributed to the additional blockade of endogenous TGFβ2 
activity. 
Overall, these findings demonstrate the novel response of hTM cells to TGFβ2 
stimulation.  We have confirmed that TGFβ2 increases COL1 protein expression, 
and that TGFβ instead of decreasing the expression of PTEN as found in previous 
studies, is inactivated PTEN by phosphorylation.  Our studies suggest that 
increased levels of active TGFβ2 likely contribute to fibrosis of the TM in POAG, 
and that PTEN is involved in this fibrotic process.  Furthermore, we continue to 
investigate PTEN as a regulator of fibrosis with the potential to be used as a 
treatment target towards preventing and mitigating dysfunction of the TM in POAG.  
However, prior to developing PTEN-targeted treatments, the mechanism of action 
of TGFβ signaling and its effect on PTEN must be deciphered.   
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Chapter 4 
4 Signaling mechanisms regulating PTEN 
4.1 Rationale 
In the previous chapter, we described the effects of TGFβ2 stimulation on hTM 
cells in vitro.  While there is evidence to support the TGFβ-induced suppression of 
PTEN protein and PTEN mRNA (39, 51, 52, 77, 78 85), we have shown a different 
mechanism of regulation of PTEN activity in hTM cells.  Although PTEN expression 
is increased, the concomitant phosphorylation of PTEN indicates its inactivation by 
TGFβ.  The phosphorylation of PTEN is accompanied by increased COL1 
production induced by TGFβ.  In Chapter 4, we build upon these findings to 
investigate potential signaling pathways that may regulate PTEN to affect activity 
and ECM protein production.   
PTEN is involved in various signaling pathways within the cell related to growth, 
differentiation, proliferation, and ultimately fibrogenesis (8, 39, 85, 89).  Of 
particular interest is involvement of PTEN with the PI3K/AKT pathway and the 
Src/FAK pathway, usually reported in the context of oncogenesis and cancer 
development (90-92). 
As introduced in Chapter 1, PTEN antagonizes PI3K activity by converting PIP3 
into PIP2.  Since PIP3 is required for AKT activation (93), PTEN is able to negatively 
regulate the PI3K/AKT pathway (70).  In turn, PI3K is also able to negatively 
regulate PTEN activity (94, 95). Similarly, PTEN is involved in the regulation of 
FAK (73, 96).  Both pathways are able to initiate signaling cascades that increase 
ECM production, contributing to fibrosis (65, 67, 97, 98).  Here we investigate 
TGFβ-mediated activation of these pathways to determine their role in the 
regulation of PTEN. In addition, preliminary investigations on the role of the FAK 
pathway in PTEN-mediated collagen deposition were conducted because FAK has 
an important role in fibrosis (98) and PTEN is known to dephosphorylate FAK (72, 
73) to downregulate FAK signaling.  
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4.2 Background 
4.2.1 PI3K/AKT Pathway 
Non-canonical TGFβ signaling has been reported to involve the PI3K/AKT 
pathway, including evidence that TGFβ is directly able to activate PI3K by inducing 
tyrosine phosphorylation (52).  The PI3K/AKT pathway is highly involved in cell 
cycle regulation and various cellular processes, including downstream TGFβ 
signaling and ECM deposition (55).  We are particularly interested in this pathway 
because PTEN is a direct antagonist of PI3K, and PI3K is known to negatively 
regulate PTEN (94, 95) in a feedback mechanism that can enhance signaling 
through AKT.   
There are a total of eight known PI3K isoforms, divided into three classes based 
on structure and substrate affinity (99).  Class I PI3Ks use PIP2 as a substrate and 
exist in association with a regulatory subunit.  The main isoforms in this class are 
PI3K α, β, γ, and δ (100).  PI3K α/β/γ/δ are found in all mammalian cell types (101).  
PI3Ks α/β/δ forms a complex with a p85 regulatory subunit, whereas PI3Kγ binds 
with either a p101 or p87 regulatory subunit (100).  Individual roles of the regulatory 
subunits have yet to be determined, but it is suggested they exist to stabilize PI3K 
and inhibit kinase activity in the absence of a stimulus, and recruit PI3K to activated 
receptors.  Class I PI3Ks are the most studied and best understood. 
Class II and III PI3Ks use phosphatidylinositol lipids as substrates (99).  There are 
three isoforms classified as Class II PI3Ks, which have some role in signal 
transduction (102) although the mechanism and significance has not yet been 
clearly defined.  The physiological role of Class III PI3Ks is still poorly understood, 
although some evidence has suggested they are involved in endosomal protein 
sorting and autophagy. 
We focus on Class I PI3Ks as their main function, to phosphorylate PIP2 into PIP3, 
is directly antagonized by the action of PTEN (Figure 4.2.1).  Deviations in PTEN 
signaling, or inactivation of PTEN by its phosphorylation (at residues 
Ser380/Thr382/383) leave PI3K relatively unopposed to increase signaling 
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through this pathway.  Cancer associated mutations in Class I PI3K isoforms are 
associated with increased basal levels of kinase activity, resulting in increased 
AKT activation (103).  Currently, clinical trials are underway using inhibitors to 
Class I PI3K isoforms to treat cancers with associated PI3K mutations (104).  In 
terms of PI3K’s regulation of PTEN, investigations by Tzenaki et al. have shown 
that the p110δ subunit of PI3K is able inactivate PTEN (95).  Tzenaki has shown 
that overexpression of the p110δ PI3K subunit in prostate and breast cancer cells 
results in decreased PTEN activity and increased phosphorylation of AKT (95).  
PTEN activity is restored and phosphorylation of AKT is decreased upon 
inactivation of the p110δ PI3K subunit (95). 
 
Figure 4.2.1 Schematic representation of PI3K/AKT pathway with active and 
inactive PTEN.   
(A) TGFβ is reported to signal through a non-canonical pathway involving PI3K/AKT to increase 
ECM production (85).  Normally, PI3K phosphorylates PIP2 into PIP3, which is required for AKT 
activation.  PTEN exerts it phosphatase activity to counteract the effects of PI3K, dephosphorylating 
PIP3 into PIP2.  The actions of both PI3K and PTEN work to control AKT signaling in favour of 
maintaining homeostatic conditions.  (B) When PTEN is phosphorylated to become inactive, PI3K 
activity is unopposed, leading to increased intracellular concentrations of PIP3.  AKT is then 
activated at an increasing rate and for a prolonged response.  Alternatively, the p110δ PI3K subunit 
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is also able inactivate PTEN (as shown by the red arrow) (95).  This mechanism also results in 
increased AKT activation.  
AKT is a key mediator of downstream metabolic effects induced by cell stimuli 
including growth factors and hormones.  PIP3 is able to bind the pleckstrin 
homology (PH) domain of AKT to activate the molecule (105).  Once activated, 
AKT localizes to the plasma membrane where it interacts with other kinases (93, 
106).  Kinases phosphorylate AKT to propagate cell signals and elicit downstream 
effects related to cell proliferation, migration, survival, and ultimately, fibrogenesis 
(93, 107). Increases in AKT activity are seen with phosphorylation of Thr308 (93, 
107).  Rapid and more intense activation is seen when Ser473 is phosphorylated 
along with Thr308 (93).  Activated AKT can be confirmed by the phosphorylation 
of its Ser473 residue.  Furthermore, activated AKT (pAKT) has been shown to be 
involved in ECM deposition and implicated in fibrotic processes (7, 8, 39, 55). 
4.2.2 Src/FAK Pathway 
The Src/FAK pathway is involved in cell adhesion, migration, and survival signals, 
and has also been implicated in fibrogenesis (65, 66, 97, 108, 109).  Specifically, 
FAK protein is found in focal adhesions along with other structural components 
that connect the cellular cytoskeleton to the ECM (97).  Activation of FAK can occur 
through integrin signaling, as activated integrins induce FAK to autophosphorylate 
at Tyr397 (110, 111).  Alternatively, Tyr397 phosphorylation is mediated by growth 
factor signaling (64, 112).  Most importantly, activation of FAK is necessary for 
binding of Src and subsequent signal amplification (110).   
Src is ubiquitously expressed in all cells and involved in FAK signaling.  Activation 
of Src can occur through external stimuli as sensed by receptors, particularly 
adhesion and cytokine receptors (113).  Prior to activation, dephosphorylation of 
Src residue Tyr527 must occur (114).  Src protein is then destabilized to reveal the 
kinase domain, which allows for autophosphorylation at tyrosine residue 416 to 
increase activity. Activated Src is recruited to sites of tyrosine phosphorylation 
(specifically Tyr397) on activated FAK.  Once activated Src binds to activated FAK, 
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Src is able to phosphorylate additional residues on FAK to increase signal 
transduction and propagation (115).    
As mentioned in Chapter 1, the protein phosphatase activity of PTEN allows for 
regulation FAK and Src signaling.  PTEN removes phosphorylation of tyrosine 
residues, including phosphate groups on residues that are responsible for the 
activation of FAK (72, 73).   
Tamura and colleagues used PTEN-deficient glioblastoma and breast cancer cells 
to determine the mechanism by which PTEN regulates FAK (72).  Results showed 
that PTEN regulates FAK phosphorylation. In control cells that lacked PTEN 
expression, FAK phosphorylation was maintained even after FAK was no longer 
actively signaling because it was attached to the ECM (72).  Increased levels of 
PIP3, increased PI3K activity, and phosphorylation of AKT were also found in 
PTEN-deficient cells.  Expressing PTEN in these cells reversed this phenotype.  
The phenotype was partially restored in cells that were exogenously expressing 
PTEN upon overexpression of FAK (72).   
Furthermore, the investigators found Tyr397 phosphorylation of FAK was 
necessary for intracellular association of PTEN (72).  When cells were detached 
from the ECM, FAK was quickly dephosphorylated in cells that expressed wild-
type PTEN, while phosphorylation of FAK was retained in PTEN-deficient cells 
after detachment from the matrix, suggesting that PTEN regulates FAK by 
dephosphorylating it (72). 
Several studies have established FAK as a major mediator of fibrogenesis (65, 66 
97, 98, 108, 109).  In a study of idiopathic pulmonary fibrosis (109), 
immunohistochemical analysis of lung tissue samples from patients showed 
increased FAK expression and increased staining of pFAK (Tyr925) in comparison 
to healthy controls (109).  The study also investigated a murine model of 
bleomycin-induced lung fibrosis and found that pharmacological and si-RNA 
mediated inhibition of FAK prevented progression of fibrosis. It was further found 
FAK-deficient fibroblasts did not undergo myofibroblast differentiation.  Overall, the 
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investigators concluded that FAK seems to be mediating fibrosis in lung fibroblasts 
and has the potential to be involved in fibrogenesis of other tissues (109).  We 
want to investigate the role of the Src/FAK pathway and its interaction with PTEN 
in the TGFβ-induced fibrosis of hTM cells. 
4.3 Experimental Approach 
1. To determine involvement of PI3K/AKT pathway in the regulation of PTEN 
by TGFβ-mediated signaling with the use of specific PI3K isoform inhibitors 
LY294002 and ZSTK474.  Protein expression levels will be analyzed using 
immunoblots.  Activity of PTEN will be assessed by analyzing levels of 
pPTEN. 
2. To determine the involvement of the Src/FAK pathway in the regulation of 
PTEN by TGFβ-mediated signaling with the use of Src/FAK inhibitor PP2.  
Protein expression levels will be analyzed using immunoblots.  Activity of 
PTEN will be assessed by analyzing levels of pPTEN. 
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4.4 Results 
4.4.1 PI3K/AKT Pathway 
4.4.1.1 TGFβ2 increases phosphorylation of AKT. 
Intracellular TGFβ signaling is quite complex and involves cross-talk of multiple 
different pathways.  We wanted to identify candidate pathways through which 
TGFβ2 may mediate its pro-fibrotic effects.   After culturing hTM cells on pronectin-
coated plates using varying levels of TGFβ2 (1, 5, and 10ng/mL) we observed at 
least 2-fold increases in the relative expression of pAKT in comparison to control 
at 24 (Figure 4.4.1) and 48 hours (Figure 4.4.2).  The increase in pAKT was 
statistically significant with TGFβ2 1ng/mL and 5ng/mL (p<0.05 each) and TGFβ2 
10ng/mL (p<0.01) at 24 hours.  No relative change was observed in the total level 
of AKT at 24 or 48 hours. The fold change in relative pAKT expression with addition 
TGFβ2 was much higher at 24 hours suggesting early involvement of the 
PI3K/AKT signaling pathway.  At both 24 and 48 hours, the level of pAKT returned 
to near control levels upon pretreatment with SB431542, a TGFβ receptor inhibitor. 
 
 
45 
 
 
Figure 4.4.1 TGFβ2 increases phosphorylation of AKT at 24 hours. 
Immunoblots from hTM cells treated with increasing concentrations of TGFβ2 (1, 5, or 10ng/mL), 
and TGFβ receptor inhibitor SB431542 (20µM). Protein was extracted at 24 hours (A).  
Immunoblots were probed with antibodies for pAKT (Ser473), AKT, and GAPDH.  Levels of AKT 
protein expression did not vary drastically with addition of TGFβ2 (1, 5, or 10ng/mL).  Increases in 
pAKT were seen with increasing amounts of TGFβ2 (1, 5, or 10ng/mL).  Increases in AKT 
phosphorylation were prevented by pretreatment with SB431542 (20µM) prior to addition of TGFβ2 
5ng/mL. Densitometry for 24 hour pAKT (B) and AKT (C).  Data was analyzed using one-way 
ANOVA.  The source of statistical significance was determined by applying Tukey’s post-hoc test 
(GraphPad Prism); N=3. 
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Figure 4.4.2 Expression of phosphorylated AKT 48 hours after TGFβ2 
treatment. 
Immunoblots from hTM cells treated with increasing concentrations of TGFβ2 (1, 5, or 10ng/mL), 
and TGFβ receptor inhibitor SB431542 (20µM). Protein was extracted at 48 hours (D).  
Immunoblots were probed with antibodies for pAKT (Ser473), AKT, and GAPDH.  Levels of AKT 
protein expression did not vary drastically with addition of TGFβ2 (1, 5, or 10ng/mL).  Changes in 
pAKT (Ser473) expression were not statistically significant. Densitometry for 48 hour pAKT (E) and 
AKT (F).  Data was analyzed using one-way ANOVA; N=3. 
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4.4.1.2 Inhibition of PI3K with LY294002 decreases COL1 protein 
expression. 
To investigate downstream TGFβ-signaling pathways we inhibited PI3K with 
LY294002, a pan-PI3K inhibitor with increased specific affinity for the PI3Kα/β/δ 
isoforms.  hTM cells were cultured on plastic plates using TGFβ2 (1ng/mL) and 
LY294002 at 20 and 30µM.  As expected, TGFβ2 significantly increased (p<0.01) 
COL1 protein expression in comparison to control (Figure 4.4.3).  Upon addition 
of LY20µM to TGFβ-treated cells, COL1 levels significantly decreased (p<0.001) 
in comparison to cells treated with TGFβ2 (1ng/mL) alone.  Even greater 
decreases in COL1 expression were observed with higher concentrations of 
inhibitor (p<0.0001 for LY30µM), decreasing COL1 expression below baseline 
levels.   TGFβ2 is able to induce increases in collagen, but these increases are 
prevented in the presence of a PI3Kα/β/δ isoform inhibitor suggesting that AKT 
signaling is involved in collagen expression. 
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Figure 4.4.3 Inhibition of PI3K with LY294002 decreases COL1 protein 
expression. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and pan-PI3K inhibitor LY294002 (20 
and 30µM).  Protein was extracted at 24 hours (A).  Immunoblots were probed with antibodies for 
COL1 and GAPDH.  Levels of TGFβ2-induced COL1 protein expression were decreased following 
pretreatment with increasing concentrations of LY294002.  Densitometry for 24 hour data (B).  Data 
was analyzed using one-way ANOVA.  The source of statistical significance was determined by 
applying Tukey’s post-hoc test (GraphPad Prism).  **p<0.01, ***p<0.001, ****p<0.0001; N=3. 
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4.4.1.3 Inhibition of PI3K with LY294002 decreases PTEN protein 
expression and phosphorylation of PTEN. 
To investigate the role of PTEN in downstream TGFβ-signaling we inhibited PI3K 
with LY294002, a pan-PI3K inhibitor with increased specific affinity for the 
PI3Kα/β/δ isoforms.  hTM cells were cultured on plastic plates using TGFβ2 
(1ng/mL) and LY294002 at 20 and 30 µM.   Expression of both PTEN and pPTEN 
decreased 24 hours after treatment with a PI3K inhibitor to block PI3K/AKT 
signaling (Figure 4.4.4).  Total PTEN expression significantly decreased (p<0.001 
for LY20 µM and LY30µM) for cells pretreated before addition of TGFβ2, in 
comparison to cells treated with TGFβ2 alone.  Phosphorylation of PTEN 
subsequently decreased significantly (p<0.05 for LY20 µM; p<0.01 for LY30µM) in 
comparison to TGFβ2-treated cells.  A comparison of the relative levels of pPTEN 
to total PTEN across various treatments showed no significant changes.  TGFβ2 
is able to induce increases in PTEN and pPTEN, but these increases are not as 
high in the presence of a PI3Kα/β/δ isoform inhibitor, suggesting a role for this 
pathway in the modulation of PTEN. 
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Figure 4.4.4 Inhibition of PI3K with LY294002 decreases PTEN protein 
expression and phosphorylation. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and pan-PI3K inhibitor LY294002 (20 
and 30µM). Protein was extracted at 24 hours (A).  Immunoblots were probed with antibodies for 
PTEN, pPTEN, and GAPDH.  Levels of PTEN protein expression were decreased following 
pretreatment with increasing concentrations of LY294002.  Decreases in pPTEN were also 
observed.  Densitometry for 24 hour PTEN (B), pPTEN (C), and relative pPTEN/PTEN expression 
(D). Data was analyzed using one-way ANOVA.  The source of statistical significance was 
determined by applying Tukey’s post-hoc test (GraphPad Prism). *p<0.05, **p<0.01, ***p<0.001; 
N=3. 
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4.4.1.4 Phosphorylation of AKT after inhibition of PI3K with 
LY294002.  
To confirm that inhibition of PI3K prevents signaling through AKT, we probed for 
levels of pAKT 24 hours after treatment with TGFβ2 and with inhibitors.  hTM cells 
cultured on plastic plates using TGFβ2 (1ng/mL) and pan-PI3K inhibitor 
(LY294002 at 20 and 30 µM) show changes in pAKT (Ser473) at 24 hours in 
comparison to cells treated with TGFβ2 (1ng/mL) alone (Figure 4.4.5).  All cells 
treated with LY294002 at either concentration have barely detectable levels of 
pAKT.  pAKT expression after treatment with PI3K inhibitor decreased below 
expression levels seen in control cells.  Immunoblot analysis is consistent with the 
results presented in Figure 4.4.8, supporting the hypothesis that TGFβ signaling 
to induce COL1 expression requires PI3K activation of AKT. The absence of pAKT 
suggests inhibition of PI3Kα/β/δ isoforms successfully blocks AKT signaling for 
collagen expression. 
 
Figure 4.4.5 Phosphorylation of AKT after inhibition of PI3K with LY294002. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and pan-PI3K inhibitor LY294002 (20 
and 30µM). Protein was extracted at 24 hours.  Immunoblots were probed with antibodies for pAKT 
(Ser473), AKT, and GAPDH.  Levels of AKT protein expression did not change with addition of 
PI3K inhibitors.  Changes to expression of pAKT seen 24 hours after treatment with TGFβ2 and 
LY294002 are consistent with the hypothesis that COL1 expression induced by TGFβ2 requires 
activation of the PI3K/AKT pathway.   
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4.4.1.5 Inhibition of PI3K with ZSTK474 decreases COL1 protein 
expression. 
To further confirm the role of PI3K signaling in PTEN-mediated collagen 
expression, we inhibited PI3K signaling in TGFβ2 treated hTM cells using another 
inhibitor- ZSTK474.  hTM cells were cultured on plastic plates using TGFβ2 
(1ng/mL) and ZSTK474 at 2 and 5µM.  Although TGFβ2 treatment increased COL1 
expression at 24 hours, pretreatment with increasing concentrations of ZSTK474 
rescued this effect in a dose-dependent manner (Figure 4.4.6).  Cells pretreated 
with ZSTK474 exhibited significantly decreased levels of COL1 (p<0.01 for Z2, and 
p<0.001 for Z5 µM) in comparison to cells treated with TGFβ2 alone.  Cells treated 
with inhibitor alone also exhibited decreases in COL1 expression below baseline 
levels.  TGFβ2 is able to induce increases in collagen, but these increases are 
prevented in the presence of a PI3K inhibitor suggesting that signaling through 
AKT is involved in collagen expression. 
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Figure 4.4.6 Inhibition of PI3K with ZSTK474 decreases COL1 protein 
expression.  
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and PI3K inhibitor ZSTK474 (2 and 
5µM).  Protein was extracted at 24 hours (A).  Immunoblots were probed with antibodies for COL1 
and GAPDH.  Levels of TGFβ2-induced COL1 protein expression were decreased following 
pretreatment with increasing concentrations of ZSTK474.  Densitometry for 24 hour COL1 (B).  
Data was analyzed using one-way ANOVA.  The source of statistical significance was determined 
by applying Tukey’s post-hoc test (GraphPad Prism).  **p<0.01, ***p<0.001; N=3. 
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4.4.1.6 Inhibition of PI3K with ZSTK474 decreases PTEN protein 
expression and phosphorylation of PTEN. 
Next, we wanted to further investigate the role of PTEN in downstream TGFβ-
signaling when PI3K activity was inhibited by specific inhibitor ZSTK474.  Cultures 
of hTM cells on plastic plates using TGFβ2 (1ng/mL) and ZSTK474 at 2 and 5 µM 
show significant decreases (p<0.001 for Z2 µM; p<0.0001 for Z5 µM) in PTEN 
protein levels in comparison to cells treated with TGFβ2 alone (Figure 4.4.7).  
TGFβ2 significantly increased levels of pPTEN (p<0.05).  As seen with the 
PI3Kα/β/δ isoform inhibitor, pretreatment with the higher inhibitor concentration (Z5 
µM) prior to addition of TGFβ2 was sufficient to significantly decrease (p<0.01) 
pPTEN in comparison to TGFβ2-treated cells.  Overall, expression of both PTEN 
and pPTEN levels decreased upon pretreatment with PI3K inhibitors to block 
PI3K/AKT signaling.  There were no significant changes to the relative ratio of 
pPTEN to total PTEN across various treatments.  Although TGFβ2 is able to induce 
increases in PTEN and pPTEN, this response is dampened in the presence of a 
PI3Kδ inhibitor suggesting a role for this pathway in the modulation of PTEN. 
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Figure 4.4.7 Inhibition of PI3K with ZSTK474 decreases PTEN protein 
expression and phosphorylation. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and PI3K inhibitor ZSTK474 (2 and 
5µM). Protein was extracted at 24 hours (A).  Immunoblots were probed with antibodies for PTEN, 
pPTEN, and GAPDH.  Levels of PTEN protein expression were decreased following pretreatment 
with increasing concentrations of ZSTK474.  Decreases in pPTEN were also observed.  
Densitometry for 24 hour PTEN (B), pPTEN (C), and relative pPTEN/PTEN (D) expression.  Data 
was analyzed using one-way ANOVA.  The source of statistical significance was determined by 
applying Tukey’s post-hoc test (GraphPad Prism). *p<0.05, **p<0.01, ***p<0.001; N=3. 
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4.4.1.7 Inhibition of PI3K with ZSTK474 decreases phosphorylation 
of AKT. 
To further confirm that inhibition of PI3K prevents signaling through AKT, we 
checked for levels of pAKT 24 hours after treatment with TGFβ2 and inhibitors.  
hTM cells cultured on plastic plates using TGFβ2 (1ng/mL) and specific PI3K 
inhibitors (ZSTK474 at 2 and 5 µM).  All cells treated with ZSTK474 express very 
low levels of pAKT; even in comparison to control cells (Figure 4.4.8).  Cells 
treated with ZSTK474 show decreases in pAKT (Ser473) at 24 hours (p<0.01) in 
comparison to cells treated with TGFβ2 (1ng/mL) alone.  Changes to expression 
of pAKT seen 24 hours after treatment with TGFβ2 and ZSTK474 are similar to 
the changes seen 24 hours after inhibition LY294002.  The absence of pAKT 
suggests that inhibition of PI3K successfully blocks AKT signaling for collagen 
expression. 
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Figure 4.4.8 Inhibition of PI3K with ZSTK474 decreases phosphorylation of 
AKT. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and PI3K inhibitor ZSTK474 (2 and 
5µM). Protein was extracted at 24 hours.  Immunoblots were probed with antibodies for pAKT 
(Ser473), AKT, and GAPDH.  Levels of AKT protein expression did not change with addition of 
PI3K inhibitors.  Levels of pAKT expression were decreased following pretreatment with increasing 
concentrations of ZSTK474.   
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4.4.2 Src/FAK  
4.4.2.1 Phosphorylation of FAK after TGFβ2 treatment. 
After culturing hTM cells on pronectin-coated plates using varying levels of TGFβ2 
(1, 5, and 10ng/mL) and TGFβ receptor inhibitor SB431542 (20 µM) we 
investigated involvement of the Src/FAK pathway.  While visual analysis of the 
immunoblots at 24 (Figure 4.4.9) and 48 hours (Figure 4.4.10) seemed to indicate 
that pFAK (Tyr397) was increased with TGFβ2 treatment, subsequent 
densitometric and statistical analysis determined the changes to be non-
significant.   
 
 
 
59 
 
 
Figure 4.4.9 Phosphorylation of FAK 24 hours after TGFβ2 treatment. 
Immunoblots from hTM cells treated with increasing concentrations of TGFβ2 (1, 5, or 10ng/mL), 
and TGFβ receptor inhibitor SB431542 (20µM). Protein was extracted at 24 hours (A).  
Immunoblots were probed with antibodies for pFAK (Tyr397), FAK, and GAPDH.  Levels of FAK 
protein expression did not vary drastically with addition of TGFβ2 (1, 5, or 10ng/mL).  Changes in 
pFAK with increasing amounts of TGFβ2 (1, 5, or 10ng/mL) were not determined to be statistically 
significant.  Densitometry for 24 hour pFAK (B) and FAK (C).  Data was analyzed using one-way 
ANOVA; N=3. 
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Figure 4.4.10 Phosphorylation of FAK 48 hours after TGFβ2 treatment. 
Immunoblots from hTM cells treated with increasing concentrations of TGFβ2 (1, 5, or 10ng/mL), 
and TGFβ receptor inhibitor SB431542 (20µM). Protein was extracted at 48 hours (D).  
Immunoblots were probed with antibodies for pFAK (Tyr397), FAK, and GAPDH.  Levels of FAK 
protein expression did not vary drastically with addition of TGFβ2 (1, 5, or 10ng/mL).  Changes in 
pFAK with increasing amounts of TGFβ2 (1, 5, or 10ng/mL) were not determined to be statistically 
significant. Densitometry for 48 hour pFAK (E) and FAK (F).  Data was analyzed using one-way 
ANOVA; N=3. 
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4.4.2.2 Inhibition of Src/FAK decreases COL1 protein expression. 
To investigate the involvement of the Src/FAK pathway in TGFβ-mediated collagen 
expression, we employed the Src inhibitor PP2.  hTM cells were cultured on plastic 
plates using TGFβ2 (1ng/mL) and PP2 at 10 and 20 µM.  As expected, TGFβ2 
increased COL1 protein levels significantly (p<0.01) in comparison to control 
(Figure 4.4.11).  Pretreatment with increasing concentrations of PP2 before 
TGFβ2-treatment resulted in significantly decreased (p<0.01 for P10, and p<0.001 
for P20) COL1 expression in comparison to cells treated with TGFβ2 alone.  Cells 
treated with inhibitor alone expressed less COL1 than control cells.  Although 
TGFβ2 is able to induce increases in collagen, these increases are prevented by 
a Src/FAK inhibitor, suggesting that signaling through FAK may be involved in 
collagen production. 
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Figure 4.4.11 Inhibition of Src/FAK decreases COL1 protein expression. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and Src/FAK inhibitor PP2 (10 and 
20µM).  Protein was extracted at 24 hours (A).  Immunoblots were probed with antibodies for COL1 
and GAPDH.  Levels of TGFβ2-induced COL1 protein expression were decreased following 
pretreatment with increasing concentrations of Src/FAK inhibitor.  Densitometry for 24 hour data of 
hTM cells treated with Src/FAK inhibitor (B).  Data was analyzed using one-way ANOVA.  The 
source of statistical significance was determined by applying Tukey’s post-hoc test (GraphPad 
Prism).  **p<0.01, ***p<0.001; N=3. 
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4.4.2.3 Inhibition of Src/FAK decreases PTEN protein expression and 
phosphorylation of PTEN. 
We wanted to investigate whether inhibition of the Src/FAK pathway leads to 
changes in PTEN.  hTM cells were culture on plastic plates using TGFβ2 (1ng/mL) 
and Src/FAK inhibitor (PP2 at 10 and 20 µM).  Upon treatment with TGFβ2 we 
have a significant increase (p<0.05) in PTEN, followed by a significant increase 
(p<0.01) in pPTEN (Figure 4.4.12).  Pretreatment with 10µM PP2 before TGFβ2 
treatment significantly decreased PTEN and pPTEN (p<0.05 for both) expression 
in comparison to TGFβ2-treated cells.  This effect counteracting TGFβ2-induced 
increases in PTEN and pPTEN in comparison to TGFβ2-treated cells is stronger 
at the higher inhibitor concentration, as TGFβ2 with PP2 20µM decreased PTEN 
and pPTEN protein levels roughly 0.35-fold more that TGFβ2 and PP2 10 µM 
treatment.  Similar to experiments with the PI3K inhibitors, the ratio of pPTEN to 
total PTEN was not significantly different across various treatments.  Again, since 
TGFβ2 is able to induce increases in pPTEN and PTEN, which can be prevented 
in the presence of a Src/FAK inhibitor, PTEN may be signaling through FAK to 
induce collagen expression. 
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Figure 4.4.12 Inhibition of Src/FAK decreases PTEN protein expression and 
phosphorylation. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and Src/FAK inhibitor PP2 (10 and 
20µM).  Protein was extracted at 24 hours (A).  Immunoblots were probed with antibodies for PTEN, 
pPTEN, and GAPDH.  Levels of PTEN protein expression were decreased following pretreatment 
with increasing concentrations of Src/FAK inhibitor.  Decreases in pPTEN were also observed.  
Densitometry for 24 hour PTEN (B), pPTEN (C), and relative pPTEN/PTEN (D) expression. Data 
was analyzed using one-way ANOVA.  The source of statistical significance was determined by 
applying Tukey’s post-hoc test (GraphPad Prism). *p<0.05, **p<0.01, ***p<0.001; N=3. 
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4.4.2.4 Inhibition of Src/FAK shows variable changes in 
phosphorylation of FAK. 
To investigate changes occurring in the Src/FAK pathway as a result of inhibition 
we cultured hTM cells on plastic plates using TGFβ2 (1ng/mL) and Src/FAK 
inhibitor (PP2 at 10 and 20 µM).  Consistent with the results presented in Figure 
4.4.9 we do not show significant increases in pFAK with TGFβ2 treatment after 24 
hours.  We also fail to see consistent changes in pFAK 24 hours after treatment 
with a Src inhibitor (Figure 4.4.13).  Interestingly, some donors seem to decrease 
activation of the Src/FAK pathway after treatment with Src inhibitor PP2, while 
others seem to be insensitive to it, continuing to express pFAK.   
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Figure 4.4.13 Inhibition of Src/FAK shows no consistent change in 
phosphorylation of FAK at 24 hours. 
Immunoblots from hTM cells treated with TGFβ2 (1ng/mL), and Src/FAK inhibitor PP2 (10 and 
20µM).  Protein was extracted at 24 hours (A).  Immunoblots were probed with antibodies for pFAK 
(Tyr397), FAK, and GAPDH.  Levels of FAK protein expression remained relatively constant 
regardless of treatment applied.  Changes in FAK phosphorylation (Tyr397) were not statistically 
significant. Densitometry for 24 hour pFAK (B) and FAK (C).  Data was analyzed using one-way 
ANOVA (GraphPad Prism).  N=3. 
 
67 
 
4.4.3 Summary of Results 
1. TGFβ2 increased pAKT protein expression. 
2. Inhibition of PI3K decreased COL1 expression. 
3. Inhibition of PI3K decreased pPTEN expression. 
4. Inhibition of Src decreased COL1 expression. 
5. Inhibition of Src decreased pPTEN expression. 
4.5 Discussion 
Here we show that TGFβ2 utilizes a non-canonical signaling pathway involving 
PI3K/AKT to induce COL1 expression.  Additionally, our preliminary investigations 
also show involvement of the Src/FAK pathway. 
Treatment of hTM cells with TGFβ2 increased Ser473 phosphorylation of AKT, 
indicating activation of the AKT pathway.  We find that activation of AKT 
(Appendix C) and phosphorylation of PTEN (Appendix D) occur at early time 
points under TGFβ2 stimulation, and after 24 hours the increased pAKT and 
pPTEN expression is seen concomitant to increases in COL1 expression.  This 
further supports the role of PTEN phosphorylation in the inactivation of PTEN 
allowing for increased signaling through AKT and increased COL1 expression.  
This is consistent with other reports that AKT activation contributes to a fibrotic 
phenotype (7, 8, 39, 55).   
Similar results were reported in Pten-deficient dermal fibroblasts, which showed 
increased pAKT expression along with increased expression of COL1 (7).  COL1 
expression decreased after Pten-deficient fibroblasts were treated with PI3K 
inhibitors LY294002 and wortmannin (an irreversible PI3K inhibitor), supporting the 
PI3K/AKT-dependent mechanism of fibrogenesis (7).  In our study, we also found 
PI3K inhibitors LY294002 and ZSTK474 decreased COL1 expression induced by 
TGFβ2.  The decrease in COL1 was accompanied by decreases in pPTEN and 
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pAKT, suggesting increased PTEN activity prevented activation of the AKT 
pathway.  In fact, we show that inhibition of PI3K nearly ablates all expression of 
phosphorylated AKT.  Decreased pAKT expression is also seen in our experiments 
with the TGFβR inhibitor SB431542, denoting that the effect is TGFβ-specific 
activation of the PI3K/AKT pathway.   
One interesting result is the decreased expression of total PTEN protein, which is 
observed along with decreased expression of pPTEN. Despite observing 
significant differences in levels of pPTEN and PTEN between treatments, the 
relative level of pPTEN to PTEN was not significantly different. This could occur 
for a number of different reasons that may require further investigation. The most 
likely explanation considers the stability and activity of PTEN, such that increased 
rates of enzymatic activity cause PTEN to become less stable and more quickly 
degraded (74, 85, 116).  The active, non-phosphorylated, PTEN is subject to quick 
degradation and not measured by our methods.  Examination of PTEN 
ubiquitination and degradation would further support this study. Maintaining a high 
turnover rate of active PTEN may serve as an internal control mechanism, 
preventing excess activation of a potent molecule that could promote apoptosis 
upon nuclear translocation (74). 
Another noteworthy finding from our inhibitor experiments concerns the decreased 
expression of protein relative to our controls.  Treatment with PI3K and Src/FAK 
inhibitors alone showed that expression of COL1, pAKT, and even PTEN and 
pPTEN in some cases, were expressed below baseline levels.  The effect most 
likely could be attributed to blocking the action of endogenous TGFβ2.  
Endogenous TGFβ expression is discussed in detail in section 3.5.  Alternatively, 
this response may be due to non-specific effects of inhibitors.  Since there is a 
great degree of cross-talk between the pathways that regulate ECM protein 
expression (63, 64, 85), and despite testing various concentrations of inhibitors to 
obtain the optimal dose, it is possible that the inhibitors alone may be affecting 
more than one target pathway to decrease protein expression levels below 
baseline.   
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Regarding the Src inhibition experiments, we failed to see consistent changes in 
pFAK expression.  This may be due to a number of reasons. First, FAK could have 
been dephosphorylated at an early time point by PTEN activation upon Src 
inhibition and we have only tested FAK phosphorylation at 24 hours. Second, Src 
is known to phosphorylate FAK on an additional five tyrosine residues: Tyr407 in 
the amino terminal portion, Tyr576 and Tyr577 within the catalytic domain 
(phosphorylation of which is required for maximal enzymatic activity of FAK) (117), 
and Tyr861 and Tyr925 at the carboxyl terminal of FAK (118, 119). We have only 
investigated phosphorylation of FAK at Tyr397. Other phosphorylation sites have 
to be investigated. Finally, reports of additional FAK residues that can be 
phosphorylated under different conditions provide an alternate explanation for our 
results.  While Tyr397 phosphorylation is indicative of activated FAK, the 
phosphorylation occurs specifically when FAK is clustered by integrins (96).  When 
FAK is dissociated from focal adhesions, phosphorylation occurs at Tyr925 (96).  
It is possible that while FAK cycles through association with focal adhesions, 
another tyrosine residue was phosphorylated, most likely Tyr925.   
Moreover, it has been suggested that FAK is further able to activate and signal 
through the PI3K/AKT pathway to promote cell migration and changes associated 
with the cytoskeleton and extracellular matrix (63).  A study in fibroblasts 
examining the interaction between FAK and PI3K determined that the two 
molecules can associate in vitro (63).  The same investigators found this 
association was mediated by the p85 regulatory subunit of PI3K and intracellular 
association was increased upon autophosphorylation of FAK at Tyr397 (63).  
Conclusions from the study suggest PI3K acts as an effector of FAK signaling. 
Taking these points into consideration, it is possible that FAK and PI3K in hTM 
cells interact in a manner similar as proposed in Figure 4.5.1.  Cellular association 
and signaling of PI3K and FAK could augment signaling through AKT.  By blocking 
Src activity with inhibitor PP2 in our experiments, the drastic decrease in COL1 
protein levels that we observed may be due to FAK’s inability to bind PI3K and 
propagate signals through AKT.  Furthermore, since active PTEN directly 
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antagonizes the action of PI3K, it may mitigate profibrotic signals coming from 
growth factor receptors, as well as RTKs and intergrins (also shown to activate 
FAK (111, 115)) that signal through a combined PI3K and FAK pathway.  Of 
course, the intermediary events required for TGFβ to stimulate RTKs in hTM cells 
are not defined and further experiments are required to investigate whether this 
method of signaling occurs in hTM cells.  This is further supported by the fact that 
Tamura and colleagues found FAK and the p85 subunit of PI3K to 
coimmunopercipitate from PTEN-deficient cells.  PI3K and FAK were not found to 
coimmunopercipitate in cells expressing wild-type PTEN protein suggesting FAK 
and PI3K interact in the absence of PTEN activity (72).  pAKT was also found to 
be down regulated in PTEN-expressing cells via a mechanism that may involve 
the dissociation of PI3K and FAK. 
 
Figure 4.5.1. Schematic representation of proposed TGFβ activation of 
Src/FAK and PI3K recruitment.  
(A). Signals from TGFβ binding to the TGFβR have been shown to activate receptor tyrosine kinase 
(RTK) activity through multiple intermediary events.  Activation of RTKs can induce 
autophosphorylation of FAK at Tyr 397, as well as autophosphorylation of Src at Tyr 416 (64) RTKs 
may also be able to activate PI3K.  (B).  The Src/FAK complex has also been reported to associate 
with the p85 regulatory subunit of PI3K (shown here in dark red), such that PI3K acts as an effector 
of FAK signaling (63). 
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Furthermore, recent evidence indicates that FAK is able to regulate PTEN by 
phosphorylating tyrosine residue 336 to increase phosphatase activity, protein-
lipid interaction, and overall stability of PTEN (120).  Previous reports had 
suggested that PTEN Tyr336 was targeted only by Src (70).  The reciprocal 
regulation of FAK and PTEN warrants further investigation, especially in models, 
such as TM cells, where there is a role for both of these pathways in continuous 
ECM remodeling.  
The study indicates that TGFβ2 probably regulates PTEN through multiple 
signaling pathways. Interesting future directions could involve investigating the 
effects of other kinases on PTEN stability and activity and alternate conditions 
under which phosphorylation occurs.  There have been reports that post-
translation modification of GSK3 may be involved as well (70).  Fundamentally, 
identification of pathways involved in the TGFβ-PTEN signaling axis are crucial to 
enhancing understanding of this important biological process. 
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Chapter 5 
5 The functional role of PTEN in the ECM of the TM 
5.1 Rationale 
As mentioned in Chapters 1 and 3, the role of PTEN has expanded beyond that of 
a tumor suppressor to now include the regulation of fibrosis.  Investigations in 
multiple different models, including the liver, lungs, and skin, have shown that 
deletion of the PTEN gene, or inhibition of PTEN activity can induce excess ECM 
deposition to cause fibrosis (7, 8, 39, 121). 
In Chapter 4, we investigated signaling pathways involved in the regulation of 
PTEN as part of the TGFβ-PTEN axis.  We found major involvement of the 
PI3K/AKT pathway as well as some involvement of the Src/FAK pathway. Now, 
with greater mechanistic understanding of PTEN signaling, we explore the effects 
of altered PTEN activity on COL1 expression.  Specifically, we aim to determine 
whether increasing PTEN activity is able to mitigate the effects of TGFβ2 on COL1 
expression. 
5.2 Background 
Loss-of-function mutations are common in many cancers (90-92).  When PTEN is 
unable to maintain enzymatic activity to function as a tumor suppressor, growth 
and proliferation can proceed without restriction.  To this effect, decreases in PTEN 
protein expression and indirectly PTEN activity, have been associated with fibrotic 
conditions (7, 8, 39, 121).  
A study of hepatic fibrogenesis in rats, determined that hepatic stellate cells 
expressed decreasing levels of Pten mRNA and PTEN protein as in vivo hepatic 
fibrosis progressed secondary to biliary ductal ligation (121).  
Immunohistochemical analysis of liver tissue sections revealed increasing 
amounts of connective tissue disrupting normal hepatic architecture to be 
associated with decreasing PTEN protein expression levels (121).  The 
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investigators concluded that external profibrotic stimuli were able to decrease 
PTEN expression levels in hepatic stellate cells, ultimately contributing to the 
progression of fibrosis in the liver (121).    
In their 2006 study of idiopathic pulmonary fibrosis, White and colleagues 
correlated significant loss of PTEN expression to a myofibroblastic phenotype in 
human lung biopsy samples (39).  A similar phenotype was confirmed in fibroblasts 
of Pten-deficient mice.  Pharmacological inhibition of Pten in wild-type fibroblasts 
showed increased fibrotic phenotype, as characterized by α-smooth muscle actin 
expression and activation of AKT signaling in these cells.  Overexpression of Pten 
in Pten-deficient fibroblasts rescued the fibroblast phenotype and reversed 
profibrotic changes (39).  The investigation was clearly able to show that loss of 
PTEN, whether through decreased expression or decreased activity, was able to 
promote differentiation towards a fibrotic phenotype.     
Most recently, PTEN protein expression was shown to be decreased in the dermal 
fibroblasts of patients with skin fibrosis in comparison to healthy controls (7).  
Dermal fibrosis was observed in Pten-deficient mice, which averaged a 1.5 fold 
increase in dermal thickness when compared to wild-type mice.  The increased 
thickness of the skin was associated with significantly higher tissue expression of 
collagen and pAKT.  Inhibition of the PI3K/AKT pathway decreased COL1 
expression in Pten-deficient mice, as did overexpression of PTEN (7).  This study 
provided evidence that PTEN is required to maintain normal ECM deposition and 
loss of PTEN causes fibrosis.  A subsequent report stated that loss of PTEN in 
lung fibroblasts resulted in a similar fibrotic phenotype characterized by excess 
collagen production and increased phosphorylation of AKT (8). 
PTEN is involved in regulation of the cell cycle and, by extension, growth and 
production of cellular products.  Here we directly inhibit PTEN with a 
pharmacological inhibitor to determine the effects in hTM cells. 
To manipulate PTEN activity by an alternate method we obtained vectors of 
mutated PTEN DNA from Dr. M. Iijima.  Her lab has been successful in 
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characterizing some of the actions of PTEN with the involvement of various point 
mutations.  Specifically, we employed PTEN vector C124S, designed with a 
mutation in the catalytic site replacing the cysteine residue at position 124, with a 
serine residue (122, 123).  This mutation disrupts substrate binding such that the 
C124S PTEN mutant is unable to recognize and bind to PIP2 so the mature mutant 
protein is functionally inactive (122).  Dr. Iijima and colleagues have also been 
successful in engineering an enhanced-active version of PTEN (ePTEN).  This 
particular vector contains mutations in the catalytic and C2 domains to increase 
localization and binding to the plasma membrane, as well as mutations in the C-
terminus to prevent phosphorylation, specifically at Ser380 (123, 124).  By 
preventing phosphorylation of Ser380, additional phosphorylation of the tail region 
(particularly Thr382/383) is prevented, and PTEN cannot become functionally 
inactivated by this method.  ePTEN exhibits increased PIP3 phosphatase activity 
making the synthetic PTEN enzyme 8-fold more active than wildtype PTEN (123, 
125).  In our study we investigate genetic mutants of PTEN to determine the effect 
of decreased and increased PTEN activity on the ECM of hTM cells. 
5.3 Experimental Approach 
1. To determine the role of PTEN in excess COL1 expression of hTM cells by 
inhibiting PTEN with a pharmacological inhibitor.  Protein expression levels 
will be analyzed using immunoblots.  Activity of PTEN will be assessed by 
analyzing levels of pPTEN. 
2. To investigate the effect of alterations in PTEN activity on TGFβ2-induced 
expression of COL1 by transfecting cells with mutated PTEN DNA.  Protein 
expression levels will be analyzed using immunoblots.  Activity of PTEN will 
be assessed by analyzing levels of pPTEN. 
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5.4 Results  
5.4.1 Expression of COL1 protein after inhibition of PTEN. 
To determine the functional role of PTEN in ECM remodeling we cultured hTM 
cells on plastic plates using the PTEN inhibitor VO-OHpic (concentrations from 
0.25 µM up to 5 µM).  Although visual representations of the images show 
differences in COL1 expression between the control and the highest dose of 
inhibitor (VO-OHpic 5 µM) for each donor, when pooled together the results are 
not significantly different (Figure 5.4.1).    The lack of statistical significance when 
reporting the COL1 protein fold increase can be attributed to variability in donor 
response to different concentrations of the compound.  The variability in baseline 
collagen expression between different donors is another contributing factor.  
Overall, there is a nearly five-fold average increase in COL1 expression between 
controls and hTM cells treated with 5 µM VO-OHpic. 
 
 
 
 
76 
 
 
Figure 5.4.1 Expression of COL1 protein after inhibition of PTEN. 
Immunoblots from hTM cells treated with increasing concentrations of PTEN inhibitor VO-OHpic 
(0.25µM - 5µM).  Protein was extracted at 48 hours (A). Immunoblots were probed with antibodies 
for COL1 and GAPDH.  Densitometry for 48 hour data (B). Data was analyzed using one-way 
ANOVA; N=3. 
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5.4.2 Expression of enhanced-active PTEN prevents increased COL1 
protein expression. 
To investigate the effects of increased PTEN activity on TGFβ2-induced COL1 
expression we transfected cells with an enhanced-active PTEN (ePTEN; or eV in 
Figure 5.4.2) expressing vector.  The ePTEN vector codes for a mutated version 
of PTEN that is easily able to localize to the plasma membrane and exhibits an 
eight-fold increase in enzymatic activity.  We also used a vector for the expression 
of a mutant form of PTEN (C124SV) that was inactive, corroborating results from 
section 5.4.1.  Addition of TGFβ2 to cells transfected with control vectors showed 
a significant increase (p<0.01) in COL1 expression, as expected.  We found that 
hTM cells transfected with ePTEN and then treated with a pathological dose of 
TGFβ2 (5ng/mL) exhibited a significantly decreased level of COL1 (p<0.01) in 
comparison to TGFβ2-treated controls.  Moreover, transfection with C124SV prior 
to TGFβ2 treatment caused cells to express significantly more COL1 than TGFβ2-
treated controls (p<0.05), as well as control-vector only cells (p<0.0001).   
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Figure 5.4.2 Expression of enhanced-active PTEN prevents increased COL1 
protein expression. 
Immunoblots from hTM cells transfected with 1.0µg DNA (either pcDNA3.1 + IRES GFP vector 
(control vector CV), ePTEN vector (eV), or C124S PTEN vector (C124SV) then treated with TGFβ2 
(5ng/mL).  Protein was extracted at 48 hours (A). Immunoblots were probed with antibodies for 
COL1 and GAPDH.  Cells transfected with control vectors exhibited an increase in COL1 
expression following addition of TGFβ2.  Cells transfected with ePTEN vector were observed to 
have decreased COL1 expression.  Increases in COL1 protein expression were observed in cells 
transfected with C124S vector.  Densitometry for 48 hour data (B) was performed using ImageJ 
software.  Protein expression levels were normalized to GAPDH.  The relative fold change in protein 
expression levels was determined by comparing the normalized value to the normalized control for 
each donor.  Data was analyzed using one-way ANOVA.  The source of statistical significance was 
determined by applying Tukey’s post-hoc test (GraphPad Prism). *p<0.05, **p<0.01, ****p<0.0001; 
N=3. 
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5.4.3 Expression of enhanced-active PTEN decreases 
phosphorylation of PTEN. 
To confirm efficient transfection and investigate changes in post-translational 
markers of enzyme activity we checked expression levels of PTEN and pPTEN of 
transfected cells.  Cells transfected with ePTEN did not have significantly higher 
levels of total PTEN when compared to cells transfected with control vector alone 
(Figure 5.4.3).  As expected, TGFβ2 treatment increased PTEN expression levels 
(p<0.01) in cells transfected with control vector.  Transfection with C124SV prior 
to TGFβ2-treatment also caused significantly increased (p<0.01) COL1 expression 
in comparison to control-vector only cells.  No significant difference was observed 
in COL1 protein between TGFβ2-treated control and C124SV vector-only cells.  
Finally, ePTEN transfected cells treated with TGFβ2 expressed significantly less 
(p<0.05) COL1 than TGFβ2-treated control and C124SV cells.   
Changes in pPTEN expression followed a similar trend.  Not surprisingly, C124SV 
transfected cells had significantly higher (p<0.01) levels of pPTEN compared to 
ePTEN transfected cells in the absence of TGFβ2.  Transfection with ePTEN prior 
to TGFβ2-treatment was sufficient to significantly decrease pPTEN (p<0.05 and 
p<0.001) in comparison to TGFβ2-treated control and C124SV cells, respectively.  
The ratio of pPTEN to total PTEN remained relatively unchanged across various 
treatments, most likely for reasons discussed in section 4.5.  These findings 
further suggest that PTEN expression and activity are not directly correlated in TM 
cells. 
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Figure 5.4.3 Expression of enhanced-active PTEN decreases TGFβ2-induced 
phosphorylation of PTEN. 
Immunoblots from hTM cells transfected with 1.0µg DNA (either pcDNA3.1 + IRES GFP vector, 
ePTEN vector, or C124S PTEN vector) then treated with TGFβ2 (5ng/mL).  Protein was extracted 
at 48 hours (A). Immunoblots were probed with antibodies for PTEN, pPTEN (Ser380/Thr382/383), 
and GAPDH.   Cells transfected with ePTEN vector were observed to have decreased 
phosphorylation of PTEN (Ser380/Thr382/383).  Increases in PTEN phosphorylation were 
observed in cells transfected with C124S vector.  Densitometry for 48 hour data (B, C, D) was 
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performed using ImageJ software.  Protein expression levels were normalized to GAPDH.  The 
relative fold change in protein expression levels was determined by comparing the normalized 
value to the normalized control for each donor.  Data was analyzed using one-way ANOVA.  The 
source of statistical significance was determined by applying Tukey’s post-hoc test (GraphPad 
Prism). *p<0.05, **p<0.01, ***p<0.01, ****p<0.0001; N=3. 
5.4.4 Summary of Results 
1. Pharmacological inhibition of PTEN with VO-OHpic shows a trend 
towards increased COL1 expression. 
2. Expression of enhanced-active PTEN decreased COL1 expression. 
3. Expression of PTEN with defective lipid phosphatase activity (C124S 
mutant) increased COL1 expression.  
5.5 Discussion 
Pharmacological inhibition of PTEN has been reported to increase COL1 
deposition in the literature (39).  Our findings did not show a statistically significant 
change in COL1 with different concentrations of VO-OHpic due to differences in 
individual donor response.  Each donor showed a clear increase of COL1 with 5 
µM VO-OHpic treatment with an average five-fold increase (N=3) compared to 
controls. Although increased COL1 expression is biologically significant, statistical 
significance could be achieved with additional donor samples to increase statistical 
power with a larger sample size.   
Furthermore, hTM cells were not treated with exogenous TGFβ2 in order to 
examine the effect of PTEN inhibition on baseline COL1 expression.  Since 
cultured TM cells have been shown to secrete endogenous TGFβ (58) and are 
capable of responding to secreted TGFβ in an autocrine manner (61), it is possible 
that differences in baseline endogenous TGFβ activity for each donor resulted in 
variable COL1 expression.  Endogenous TGFβ activity is presented in more detail 
in the discussions for Chapters 3 and 4.   
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Finally, various models of induced PTEN-deficiency discovered increased 
accumulation of ECM proteins, and further noted increased expression of pAKT 
subsequent to loss of PTEN expression/activity (7, 8, 39).  In fact, increased AKT 
phosphorylation was also seen in a macrophage model after administration of the 
same inhibitor used in our experiments, VO-OHpic, suggesting a mechanism by 
which the increased COL1 is seen as a result of increased PI3K signaling through 
AKT (94). 
Next, we have successfully shown that the lipid phosphatase activity of PTEN is 
crucial to its role as a negative regulator of COL1 expression.  Loss of lipid 
phosphatase activity as demonstrated by cells expressing the C124S PTEN 
mutant caused greatly increased expression of COL1.  Transfection of C124S 
PTEN alone increased COL1 expression in comparison to controls.  Since 
inactivation of PTEN is known to prevent the action of SMAD2/3 phosphatase 
(126), increased COL1 expression in C124S PTEN transfected cells might be due 
to increased SMAD signaling.  Also it is to be noted that phosphorylation of PTEN 
is increased in C124S transfected cells.  Increased phosphorylation 
(Ser380/Thr382/383) of C124S PTEN has also been reported in models of gastric 
epithelial cells (127) and pyramidal neurons (128).  The mechanisms involved in 
the phosphorylation of the C124S mutant PTEN under normal conditions are not 
well-defined (127, 128), warranting further investigation. 
Collectively, the results suggest that PTEN activity is required to maintain normal 
ECM remodeling, and that dysfunctional PTEN activity can have similar effects to 
pro-fibrotic factors present in the extracellular environment, such as TGFβ2 
present in the AH, to increase fibrosis.  Likewise, maintenance of normal PTEN 
expression and activity is required to prevent the development of cancer.  PTEN-
deficiencies have been associated with carcinogenesis (90-92), but it has recently 
been shown that as little as a 20% decrease in PTEN gene expression is sufficient 
to cause cancer, especially in breast and lymphoid tissue (129, 130).  The 
specificity of tumor localization described in this study, and the previously 
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unreported response of PTEN to TGFβ2 seen in our hTM cell experiments warrant 
further investigation of tissue-specific PTEN expression and regulation.  
Finally, with these experiments we have established that PTEN is highly regulated 
by post-translational modification of its C-terminus region and this is a predominant 
mechanism in hTM cells.  Overall, an increase in PTEN activity, about eight-fold in 
this case, can have substantial downstream effects to prevent COL1 expression.  
hTM cells transfected with the ePTEN vector, harboring mutations to prevent 
inactivation of PTEN and increase its overall activity, significantly decreased 
TGFβ2-induced COL1 expression.  The most likely mechanism by which this 
occurs, is decreased AKT signaling due to increased PTEN activity, as noted in 
other models that used PTEN overexpression or PI3K inhibitors to increase 
PTEN’s relative activity (7, 39).  Since PTEN is able to translocate to the nucleus 
in some cases and initiate apoptosis (70, 74), it is possible that increasing PTEN 
activity may cause apoptosis in some TM cells.  During the course of our 
experiments, we were able to observe increased cell-death after transfection with 
the ePTEN vector.  Although pharmacological activators of PTEN could avoid this 
problem by increasing its activity only minimally and still be useful in decreasing 
ECM production.   
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Chapter 6 
6 Conclusions 
6.1 Summary of Results 
In Chapter 3 we set out to characterize the effects of TGFβ2 on COL1 and PTEN 
protein in cultured hTM cells.  We found that TGFβ2 is able to increase COL1A1 
mRNA and COL1 protein expression, inducing a fibrotic phenotype.  We further 
discovered that TGFβ2 induced increases in PTEN mRNA and PTEN protein, 
contrary to reports in the literature.  Subsequent investigation of posttranslational 
modification of PTEN showed that TGFβ2 is able to phosphorylate PTEN to 
inactivate it in cultured hTM cells. 
 In Chapter 4, we investigated the signaling pathways involved with TGFβ2-
induced fibrosis in hTM cells and found involvement of the PI3K/AKT and the 
Src/FAK pathways.  Inhibition of PI3K decreased TGFβ2-induced collagen 
expression as well as levels of inactive pPTEN.  Inhibition of Src had a similar 
effect, decreasing TGFβ2-induced collagen expression and decreasing expression 
of pPTEN.  PI3K inhibition also decreased activation of AKT. 
Finally, in Chapter 5, we set out to determine the functional role of PTEN in the 
COL1 expression of hTM cells.  We showed that expression of a phosphatase 
activity-defective PTEN mutant increased collagen expression in hTM cells 
substantially.  Alternatively, increasing PTEN activity via expression of an 
enhanced-active PTEN mutant was able to decrease TGFβ2-induced collagen 
expression. A summary of our study is presented in Figure 6.1.1.     
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Figure 6.1.1. Summary of Experimental Study. 
TGFβ signaling in hTM cells was investigated to determine the role of PTEN in hTM cell fibrosis.  
Pharmacological inhibition of key signaling molecules in a variety of pathways, including TGFβRI, 
PI3K, Src, and PTEN itself, were used.  Inhibition of the TGFβ signal, via TGFβRI, and PI3K 
blockade, lead to decreased pPTEN expression and decreased COL1 expression.  Similar results 
were observed with Src inhibition.  Altered PTEN activity as investigated via transfection of PTEN 
mutants resulted in changes to COL1 expression, such that increased PTEN activity decreased 
COL1 expression and decreased PTEN activity increased COL1 expression. 
Overall, we found that PTEN is involved in the pathways regulating ECM 
deposition in the hTM cells. Our findings contribute to the current understanding of 
TGFβ and fibrotic signaling pathways in hTM cells as demonstrated in Figure 
6.1.2.  
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Figure 6.1.2 Summary Diagram of Fibrotic Pathways Involved in TGFβ 
signaling. 
Canonical TGFβ signaling involves SMAD effector proteins, which are able to induce fibrosis by 
directly upregulating COL1A1 transcription (43, 44).  Inhibitory SMAD7 is induced by SMAD3 to 
inhibit propagation of the TGFβ signal (43, 44), and has been reported to act as an adaptor protein 
for the p38 pathway (131).  p38 signaling is initiated in the presence of a TGFβ signal to activate 
TNF receptor associated factor6 (TRAF6) through poly-ubiquitination (131).  Activated TRAF6 is 
able to activate transforming growth-factor β activated kinase 1 (TAK1), which initiates signaling to 
MAP kinase kinase 3 and 6 (MKK3/6) to phosphorylate and activate p38 (132).  Activation of the 
p38 pathway can lead to tumor suppression, apoptosis, and increased propagation of TGFβ 
signaling, particularly by increasing transcription of the TGFβ1 gene (132).  Non-canonical TGFβ 
signaling through the PI3K/AKT and Src/FAK pathways have also been linked to fibrosis (55, 64, 
85).  Normally, PI3K phosphorylates PIP2 into PIP3, which is required for AKT activation.  PTEN 
exerts it phosphatase activity to counteract the effects of PI3K, dephosphorylating PIP3 into PIP2.  
The actions of both PI3K and PTEN work to control AKT signaling in favour of maintaining 
homeostatic conditions.  When PTEN is phosphorylated to become inactive, PI3K activity is 
unopposed, leading to increased intracellular concentrations of PIP3.  AKT is then activated at an 
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increasing rate and for a prolonged response.  Alternatively, the PI3K is also able inactivate PTEN 
(as shown by the red arrow) (95) to increase AKT activation.  We have shown in hTM cells that 
treatment with TGFβ2 results in the phosphorylation and inactivation of PTEN.  TGFβR binding can 
also activate receptor tyrosine kinase (RTK) activity through multiple intermediary events.  
Activation of RTKs can induce autophosphorylation of FAK and Src (64), to produce downstream 
fibrotic effects.  Activated RTKs may also be able to activate PI3K, to employ PI3K as an effector 
of FAK signaling (63).  Finally, PTEN has been shown by previous reports, as well as in our study, 
to be negatively regulated by TGFβ signaling (39, 51, 52, 77, 78 85).  Since TGFβ signaling 
employs various canonical and non-canonical pathways, which have been shown to have some 
degree of interaction with each other (63, 95, 131), PTEN is likely also involved in these pathways. 
6.2 Limitations of the Study 
Our investigation consisted of an in vitro cell culture model designed to investigate 
individual biological phenomena and simplify complex processes.  While allowing 
us to clearly determine the effects of TGFβ2 in isolation on hTM cells, this model 
is not necessarily representative of the physiological or pathological milieu of hTM 
cells in vivo.  As mentioned in Chapter 1, hTM cells are subjected to a variety of 
stresses, including TGFβ2 and mechanical stretch (5, 40, 41).  Mechanical stretch 
activates different pathways including p38 (133) and MAPK pathways (72, 73, 133) 
in addition to Src/FAK signaling (134).  Mechanical stretch may also utilize 
pathways predominately used for TGFβ signaling, such as the PI3K/AKT pathway 
(133). For a better understanding of the complete effects of TGFβ2 on the 
trabecular meshwork, hTM cells also must be subjected to mechanical stretch to 
validate our current findings in a more complex model.   
We are further limited by the availability of donor cells.  TM cells are harvested 
from the TM tissue, which comprises a small area of the anterior segment of the 
eye.  Unsurprisingly, only a limited quantity of cells can be obtained from the TM 
tissue and it is not necessarily feasible to perform multiple technical replicates of 
each experiment.  Moreover, we have used TM cells from humans in our study, 
which further limits our sample size.  Availability of TM tissue and the selection of 
different donors for biological replicates is limited by individual donation.  We must 
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also exclude older donors to avoid confounding results with samples derived from 
a glaucomatous patient.   
Finally, our investigation considers only one marker of fibrosis.  We study COL1 
as an indicator of fibrosis because its expression is commonly elevated in a wide 
array of fibrotic conditions (39, 55, 78, 81), and it has been shown to be expressed 
in the TM tissue (14, 15).  Investigation of additional ECM components such as: 
fibronectin, which is found in the JCT region of the TM with increased expression 
in glaucoma patients (20, 135); collagen type III, which is abundantly expressed 
throughout the TM (14, 15); and the proteoglycan decorin, which is involved in 
collagen fibril assembly (14, 19) could also be beneficial. 
6.3 Future Directions 
In this section, future directions are presented to address identified limitations and 
expand upon the findings of the current study. 
First, it is necessary to determine whether the increase in COL1 expression directly 
translates to increased ECM deposition.  Immunocytochemistry of cultured cells 
could be performed to localize expression of COL1 and other ECM proteins.  This 
should be followed up with an in-depth look at enzymes involved in ECM 
remodeling.  MMPs, TIMPs, and tissue-specific proteases are of primary interest 
(40-42).  Expression of MMP-2 should be investigated as it is reported to have 
specific affinity for COL1 (40) and to be upregulated under the influence of TGFβ 
(42).   
Second, the study should be expanded to more thoroughly investigate the 
mechanism of TGFβ signaling, including the actions of different TGFβ isoforms, as 
well as the expression of TGFβ receptors.  It would be interesting to determine to 
what degree the alternate mRNA splice variants identified by Wordinger and 
colleagues (61) are responsible for the mechanism of signaling through the TGFβ-
PTEN axis observed in our experiments. 
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Third, more direct methods of investigating PTEN activity should be employed.  
PTEN activity should be investigated directly by examining relative ratios of its 
substrate PIP3 to the end product PIP2 under various treatment conditions.  
Additionally, since increased activity of PTEN increases its rate of degradation (74, 
85, 116) examining ubiquitination of PTEN would also be beneficial. 
Fourth, it must be determined whether the mechanism of TGFβ response is altered 
in hTM cells from glaucoma patients.  Similar experiments to those presented in 
Chapters 3-5 could be performed for comparison.  It would be particularly 
interesting to determine whether increased PTEN activity is effective at reducing 
the fibrotic phenotype of these cells. 
Fifth, since PTEN is a highly regulated molecule within the cell (70) we must ensure 
that changes to PTEN activity do not affect cell viability by promoting oncogenic or 
apoptotic pathways.  Decreases in PTEN activity are usually associated with 
progression of cancer, whereas increased cell death is a concern with increased 
PTEN activity.  Reports have stated that upon translocation to the nucleus PTEN 
has the ability to initiate apoptosis (70, 74).  In fact, we noticed increased cell death 
in hTM cells transfected with enhanced-active PTEN mutant.  Since the ePTEN 
mutant exhibited approximately 8-fold increased enzymatic activity, which very 
effectively decreased COL1 expression, the crucial next step would be optimize 
the level of activation such that COL1 expression remained low and cell viability 
was not affected.  Pharmacological PTEN activators, including statins such as 
Simvastatin, Pravastatin and Fluvastatin (136) have been shown to increase PTEN 
activity by smaller increments (between 1.4-1.6 fold).  Investigation of these 
compounds is necessary to determine whether PTEN activity can be safely 
increased without inducing apoptosis.  
Finally, studies must move on to higher level models.  Initially, employing an in 
vitro culture model with mechanical stretch is necessary to understand the 
combinatory effects of these two factors. This model would also allow for further 
investigation of the mechanisms that activate endogenous TGFβ.  Once target 
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pathways are identified, targeted compounds, including specific pathway inhibitors 
or PTEN activators, can be tested to determine their efficacy on reducing TM tissue 
fibrosis and increasing aqueous outflow facility in an organ culture model (137).  
Findings could hopefully be translated to a suitable animal-model of glaucoma.  
Ideally, an inducible model of ocular-specific PTEN activation would help 
determine the efficacy of a potential therapy. 
6.4 Concluding Remarks 
Recently, PTEN has emerged as a major regulator of fibrosis and many research 
groups have implicated dysfunction of PTEN as a key component of fibrotic 
disease.  Our findings contribute to this emerging body of literature.  
Here, we present a novel mechanism by which TGFβ2 is able to phosphorylate 
and inactivate PTEN to cause increased COL1 protein expression.  The 
posttranslational mechanism of inactivation through phosphorylation has hitherto, 
to our knowledge, not been reported in TM cells or in any other model of fibrosis.  
Furthermore, we have shown that activation of PTEN has the potential to decrease 
excess ECM deposition in the TM.  Taken together, our findings begin to establish 
PTEN signaling as a fundamental mechanism by which the TM regulates ECM 
turnover to maintain rapid and continuous remodeling. 
Since little is known about the development and progression of POAG, our findings 
help to establish part of the mechanism of this complex disease process, and have 
the potential to be translated into targeted therapies.  Despite an ever increasing 
number of glaucoma patients and a clear need for better and more effective 
treatments, there have not been any new developments in glaucoma therapies in 
the past two decades. Ultimately, current treatments focus on reducing IOP, while 
none are designed to treat and prevent TM tissue dysfunction.  Here we propose 
PTEN as a druggable target that has high potential to emerge as an effective 
therapeutic for the treatment of glaucoma. 
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Appendices  
Appendix A: TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN on plastic plates. 
 
hTM cells cultured on plastic plates with TGFβ and SB431542.  Treatment with TGFβ2 
increased expression of total PTEN and phosphorylation of PTEN after 24 and 48 hours. 
 
 
 
 
Appendix B: TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN on COL1-coated plates. 
 
hTM cells cultured on COL1-coated Bioflex ™ plates with TGFβ and SB431542.  Treatment with 
TGFβ2 increased expression of total PTEN and phosphorylation of PTEN after 24 and 48 hours. 
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Appendix C: TGFβ2 increases PTEN protein expression and phosphorylation of 
PTEN at early time points. 
 
Preliminary data from hTM cells cultured on plastic plates with TGFβ2 5ng/mL.  Treatment with 
TGFβ2 increased phosphorylation of PTEN at 15 to 30 minutes.  Decreases in total and 
phosphorylated PTEN are seen at 1 hour post- TGFβ2 treatment, with variable expression and 
phosphorylation after 2 hours.  The early increase in PTEN phosphorylation may act as a feed-
back mechanism, and may explain the increase in PTEN expression at 24 hours observed in this 
study. 
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Appendix D: TGFβ2 increases phosphorylation of AKT at early time points. 
 
Preliminary data from hTM cells cultured on plastic plates with TGFβ2 5ng/mL.  Increased 
expression of pAKT in comparison to control can be seen starting at 15 minutes post-TGFβ2 
treatment.  The effect is sustained through the time course to 6 hours post-treatment.  The early 
increase in pAKT indicates that TGFβ2 may be directly affecting this pathway.   
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